BACKGROUND: We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics.

METHODS: We generate strong (Grade 1) and weak (Grade 2) recommendations based on high- (Grade A), moderate- (Grade B), and low- (Grade C) quality evidence.

RESULTS: For VTE and no cancer, as long-term anticoagulant therapy, we suggest dabigatran (Grade 2B), rivaroxaban (Grade 2B), apixaban (Grade 2B), or edoxaban (Grade 2B) over vitamin K antagonist (VKA) therapy, and suggest VKA therapy over low-molecular-weight heparin (LMWH; Grade 2C). For VTE and cancer, we suggest LMWH over VKA (Grade 2B), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C), or edoxaban (Grade 2C). We have not changed recommendations for who should stop anticoagulation at 3 months or receive extended therapy. For VTE treated with anticoagulants, we recommend against an inferior vena cava filter (Grade 1B). For DVT, we suggest not using compression stockings routinely to prevent PTS (Grade 2B). For subsegmental pulmonary embolism and no proximal DVT, we suggest clinical surveillance over anticoagulation with a low risk of recurrent VTE (Grade 2C), and anticoagulation over clinical surveillance with a high risk (Grade 2C). We suggest thrombolytic therapy for pulmonary embolism with hypotension (Grade 2B), and systemic therapy over catheter-directed thrombolysis (Grade 2C). For recurrent VTE on a non-LMWH anticoagulant, we suggest LMWH (Grade 2C); for recurrent VTE on LMWH, we suggest increasing the LMWH dose (Grade 2C).

CONCLUSIONS: Of 54 recommendations included in the 30 statements, 20 were strong and none was based on high-quality evidence, highlighting the need for further research.

CHEST 2016; 149(2):315-352

KEY WORDS: antithrombotic therapy; evidence-based medicine; GRADE approach; venous thromboembolism

ABBREVIATIONS: AT9 = 9th Edition of the Antithrombotic Guideline; AT10 = 10th Edition of the Antithrombotic Guideline; CHEST = American College of Chest Physicians; CDT = catheter-directed thrombolysis; COI = conflict of interest; CTEPH = chronic thromboembolic pulmonary hypertension; CTPA = CT pulmonary angiogram; GOC = Guidelines Oversight Committee; INR = International Normalized Ratio; IVC = inferior vena cava; LMWH = low-molecular-weight heparin; NOAC = non-vitamin K oral anticoagulant; PE = pulmonary embolism; PTS = postthrombotic syndrome; RCT = randomized controlled trial; UEDVT = upper extremity deep vein thrombosis; US = ultrasound; VKA = vitamin K antagonist

AFFILIATIONS: From McMaster University (Drs Kearon and Akl), Hamilton, ON; American University of Beirut (Dr Akl), Beirut, Lebanon; CHEST (Dr Ornelas), Glenview, IL; VA New Jersey Health Care System (Dr Blaivas), Newark, NJ; Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá (Dr Jimenez), Madrid, Spain; University of Geneva (Dr Bounameaux), Geneva, Switzerland; Leiden University Medical Center (Dr Huisman), Leiden, Netherlands; Virginia Commonwealth University (Dr King), Falls Church, VA; University of California (Dr Morris), San Diego, CA; The Ohio State University (D. Sood), Columbus, OH; Intermountain Medical Center and the University of Utah (Drs Stevens and Woller), Murray, UT; Harbor-UCLA Medical Center (Dr Vintch), Torrance, CA; The University of Ottawa and Ottawa Hospital Research Institute (Dr Wells), Ottawa, ON; Uniformed Services University of the Health Sciences (Dr Moores), Bethesda, MD.
Note on Shaded Text: In this guideline, shaded text with an asterisk (shading appears in PDF only) indicates recommendations that are newly added or have been changed since the publication of Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis (9th edition): American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Recommendations that remain unchanged since that edition are not shaded. The order of our presentation of the non-vitamin K oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) is based on the chronology of publication of the phase 3 trials in VTE treatment and should not be interpreted as the guideline panel’s order of preference for the use of these agents.

Summary of Recommendations

Choice of Long-Term (First 3 Months) and Extended (No Scheduled Stop Date) Anticoagulant

1. In patients with proximal DVT or pulmonary embolism (PE), we recommend long-term (3 months) anticoagulant therapy over no such therapy (Grade 1B).

*2. In patients with DVT of the leg or PE and no cancer, as long-term (first 3 months) anticoagulant therapy, we suggest dabigatran, rivaroxaban, apixaban, or edoxaban over vitamin K antagonist (VKA) therapy (all Grade 2B).

For patients with DVT of the leg or PE and no cancer who are not treated with dabigatran, rivaroxaban, apixaban, or edoxaban, we suggest VKA therapy over low-molecular weight heparin (LMWH) (Grade 2C).

Remarks: Initial parenteral anticoagulation is given before dabigatran and edoxaban, is not given before rivaroxaban and apixaban, and is overlapped with VKA therapy. See text for factors that influence choice of therapy.

*3. In patients with DVT of the leg or PE and cancer (“cancer-associated thrombosis”), as long-term (first 3 months) anticoagulant therapy, we suggest LMWH over VKA therapy (Grade 2C), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C), or edoxaban (Grade 2C).

Remarks: Initial parenteral anticoagulation is given before dabigatran and edoxaban, is not given before rivaroxaban and apixaban, and is overlapped with VKA therapy. See text for factors that influence choice of therapy.

*4. In patients with DVT of the leg or PE who receive extended therapy, we suggest that there is no need to change the choice of anticoagulant after the first 3 months (Grade 2C).

Remarks: It may be appropriate for the choice of anticoagulant to change in response to changes in the patient’s circumstances or preferences during long-term or extended phases of treatment.

Duration of Anticoagulant Therapy

5. In patients with a proximal DVT of the leg or PE provoked by surgery, we recommend treatment with anticoagulation for 3 months over (i) treatment of a shorter period (Grade 1B), (ii) treatment of a longer time-limited period (eg, 6, 12, or 24 months) (Grade 1B), or (iii) extended therapy (no scheduled stop date) (Grade 1B).

6. In patients with a proximal DVT of the leg or PE provoked by a nonsurgical transient risk factor, we recommend treatment with anticoagulation for 3 months over (i) treatment of a shorter period (Grade 1B) and (ii) treatment of a longer time-limited period (eg, 6, 12, or 24 months) (Grade 1B). We suggest treatment with anticoagulation for 3 months over extended therapy if there is a low or moderate bleeding risk (Grade 2B), and recommend treatment for 3 months over extended therapy if there is a high risk of bleeding (Grade 1B).

Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually).
7. In patients with an isolated distal DVT of the leg provoked by surgery or by a nonsurgical transient risk factor, we suggest treatment with anticoagulation for 3 months over treatment of a shorter period (Grade 2C), we recommend treatment with anticoagulation for 3 months over treatment of a longer time-limited period (eg, 6, 12, or 24 months) (Grade 1B), and we recommend treatment with anticoagulation for 3 months over extended therapy (no scheduled stop date) (Grade 1B).

Remarks: Duration of treatment of patients with isolated distal DVT refers to patients in whom a decision has been made to treat with anticoagulant therapy; however, it is anticipated that not all patients who are diagnosed with isolated distal DVT will be prescribed anticoagulants.

8. In patients with an unprovoked DVT of the leg (isolated distal or proximal) or PE, we recommend treatment with anticoagulation for at least 3 months over treatment of a shorter duration (Grade 1B), and we recommend treatment with anticoagulation for 3 months over treatment of a longer time-limited period (eg, 6, 12, or 24 months) (Grade 1B).

Remarks: After 3 months of treatment, patients with unprovoked DVT of the leg or PE should be evaluated for the risk-benefit ratio of extended therapy. Duration of treatment of patients with isolated distal DVT refers to patients in whom a decision has been made to treat with anticoagulant therapy; however, it is anticipated that not all patients who are diagnosed with isolated distal DVT will be prescribed anticoagulants.

9. In patients with a first VTE that is an unprovoked proximal DVT of the leg or PE and who have a (i) low or moderate bleeding risk (see text), we suggest extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 2B), and (ii) high bleeding risk (see text), we recommend 3 months of anticoagulant therapy over extended therapy (no scheduled stop date) (Grade 2B).

Remarks: Patient sex and D-dimer level measured a month after stopping anticoagulant therapy may influence the decision to stop or extend anticoagulant therapy (see text). In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually).

10. In patients with a second unprovoked VTE and who have a (i) low bleeding risk (see text), we recommend extended anticoagulant therapy (no scheduled stop date) over 3 months (Grade 1B); (ii) moderate bleeding risk (see text), we suggest extended anticoagulant therapy over 3 months of therapy (Grade 2B); or (iii) high bleeding risk (see text), we suggest 3 months of anticoagulant therapy over extended therapy (no scheduled stop date) (Grade 2B).

Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually).

11. In patients with DVT of the leg or PE and active cancer (“cancer-associated thrombosis”) and who (i) do not have a high bleeding risk, we recommend extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 1B), or (ii) have a high bleeding risk, we suggest extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 2B).

Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually).

Aspirin for Extended Treatment of VTE

*12. In patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin, we suggest aspirin over no aspirin to prevent recurrent VTE (Grade 2B).

Remarks: Because aspirin is expected to be much less effective at preventing recurrent VTE than anticoagulants, we do not consider aspirin a reasonable alternative to anticoagulant therapy in patients who want extended therapy. However, if a patient has decided to stop anticoagulants, prevention of recurrent VTE is one of the benefits of aspirin that needs to be balanced against aspirin’s risk of bleeding and inconvenience. Use of aspirin should also be reevaluated when patients stop anticoagulant therapy because aspirin may have been stopped when anticoagulants were started.

Whether and How to Anticoagulate Isolated Distal DVT

13. In patients with acute isolated distal DVT of the leg and (i) without severe symptoms or risk factors for extension (see text), we suggest serial imaging of the deep veins for 2 weeks over anticoagulation (Grade 2C) or (ii) with severe symptoms or risk factors for
extension (see text), we suggest anticoagulation over serial imaging of the deep veins (Grade 2C).

Remarks: Patients at high risk for bleeding are more likely to benefit from serial imaging. Patients who place a high value on avoiding the inconvenience of repeat imaging and a low value on the inconvenience of treatment and on the potential for bleeding are likely to choose initial anticoagulation over serial imaging.

14. In patients with acute isolated distal DVT of the leg who are managed with anticoagulation, we recommend using the same anticoagulation as for patients with acute proximal DVT (Grade 1B).

15. In patients with acute isolated distal DVT of the leg who are managed with serial imaging, we (i) recommend no anticoagulation if the thrombus does not extend (Grade 1B), (ii) suggest anticoagulation if the thrombus extends but remains confined to the distal veins (Grade 2C), and (iii) recommend anticoagulation if the thrombus extends into the proximal veins (Grade 1B).

Catheter-Directed Thrombolysis for Acute DVT of the Leg

16. In patients with acute proximal DVT of the leg, we suggest anticoagulant therapy alone over CDT (Grade 2C).

Remarks: Patients who are most likely to benefit from CDT (see text), who attach a high value to prevention of postthrombotic syndrome (PTS), and a lower value to the initial complexity, cost, and risk of bleeding with CDT, are likely to choose CDT over anticoagulation alone.

Role of Inferior Vena Cava Filter in Addition to Anticoagulation for Acute DVT or PE

17. In patients with acute DVT or PE who are treated with anticoagulants, we recommend against the use of an inferior vena cava (IVC) filter (Grade 1B).

Compression Stocking to Prevent PTS

*18. In patients with acute DVT of the leg, we suggest not using compression stockings routinely to prevent PTS (Grade 2B).

Remarks: This recommendation focuses on prevention of the chronic complication of PTS and not on the treatment of symptoms. For patients with acute or chronic symptoms, a trial of graduated compression stockings is often justified.

Whether to Anticoagulate Subsegmental PE

*19. In patients with subsegmental PE (no involvement of more proximal pulmonary arteries) and no proximal DVT in the legs who have a (i) low risk for recurrent VTE (see text), we suggest clinical surveillance over anticoagulation (Grade 2C) or (ii) high risk for recurrent VTE (see text), we suggest anticoagulation over clinical surveillance (Grade 2C).

Remarks: Ultrasound (US) imaging of the deep veins of both legs should be done to exclude proximal DVT. Clinical surveillance can be supplemented by serial US imaging of the proximal deep veins of both legs to detect evolving DVT (see text). Patients and physicians are more likely to opt for clinical surveillance over anticoagulation if there is good cardiopulmonary reserve or a high risk of bleeding.

Treatment of Acute PE Out of the Hospital

*20. In patients with low-risk PE and whose home circumstances are adequate, we suggest treatment at home or early discharge over standard discharge (eg, after the first 5 days of treatment) (Grade 2B).

Systemic Thrombolytic Therapy for PE

21. In patients with acute PE associated with hypotension (eg, systolic BP <90 mm Hg) who do not have a high bleeding risk, we suggest systemically administered thrombolytic therapy over no such therapy (Grade 2B).

*22. In most patients with acute PE not associated with hypotension, we recommend against systemically administered thrombolytic therapy (Grade 1B).

*23. In selected patients with acute PE who deteriorate after starting anticoagulant therapy but have yet to develop hypotension and who have a low bleeding risk, we suggest systemically administered thrombolytic therapy over no such therapy (Grade 2C).

Remarks: Patients with PE and without hypotension who have severe symptoms or marked cardiopulmonary impairment should be monitored closely for deterioration. Development of hypotension suggests that
Thrombolytic therapy has become indicated. Cardiopulmonary deterioration (eg, symptoms, vital signs, tissue perfusion, gas exchange, cardiac biomarkers) that has not progressed to hypotension may also alter the risk-benefit assessment in favor of thrombolytic therapy in patients initially treated with anticoagulation alone.

**Catheter-Based Thrombus Removal for the Initial Treatment of PE**

*24. In patients with acute PE who are treated with a thrombolytic agent, we suggest systemic thrombolytic therapy using a peripheral vein over CDT (Grade 2C).

Remarks: Patients who have a higher risk of bleeding with systemic thrombolytic therapy and who have access to the expertise and resources required to do CDT are likely to choose CDT over systemic thrombolytic therapy.

*25. In patients with acute PE associated with hypotension and who have (i) a high bleeding risk, (ii) failed systemic thrombolysis, or (iii) shock that is likely to cause death before systemic thrombolysis can take effect (eg, within hours), if appropriate expertise and resources are available, we suggest catheter-assisted thrombus removal over no such intervention (Grade 2C).

Remarks: Catheter-assisted thrombus removal refers to mechanical interventions, with or without catheter directed thrombolysis.

**Pulmonary Thromboendarterectomy for the Treatment of Chronic Thromboembolic Pulmonary Hypertension**

*26. In selected patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are identified by an experienced thromboendarterectomy team, we suggest pulmonary thromboendarterectomy over no pulmonary thromboendarterectomy (Grade 2C).

Remarks: Patients with CTEPH should be evaluated by a team with expertise in treatment of pulmonary hypertension. Pulmonary thromboendarterectomy is often lifesaving and life-transforming. Patients with CTEPH who are not candidates for pulmonary thromboendarterectomy may benefit from other mechanical and pharmacological interventions designed to lower pulmonary arterial pressure.

**Thrombolytic Therapy in Patients With Upper Extremity DVT**

27. In patients with acute upper extremity DVT (UEDVT) that involves the axillary or more proximal veins, we suggest anticoagulant therapy alone over thrombolysis (Grade 2C).

Remarks: Patients who (i) are most likely to benefit from thrombolysis (see text); (ii) have access to CDT; (iii) attach a high value to prevention of PTS; and (iv) attach a lower value to the initial complexity, cost, and risk of bleeding with thrombolytic therapy are likely to choose thrombolytic therapy over anticoagulation alone.

28. In patients with UEDVT who undergo thrombolysis, we recommend the same intensity and duration of anticoagulant therapy as in patients with UEDVT who do not undergo thrombolysis (Grade 1B).

**Management of Recurrent VTE on Anticoagulant Therapy**

*29. In patients who have recurrent VTE on VKA therapy (in the therapeutic range) or on dabigatran, rivaroxaban, apixaban, or edoxaban (and are believed to be compliant), we suggest switching to treatment with LMWH at least temporarily (Grade 2C).

Remarks: Recurrent VTE while on therapeutic-dose anticoagulant therapy is unusual and should prompt the following assessments: (1) reevaluation of whether there truly was a recurrent VTE; (2) evaluation of compliance with anticoagulant therapy; and (3) consideration of an underlying malignancy. A temporary switch to LMWH will usually be for at least 1 month.

*30. In patients who have recurrent VTE on long-term LMWH (and are believed to be compliant), we suggest increasing the dose of LMWH by about one-quarter to one-third (Grade 2C).

Remarks: Recurrent VTE while on therapeutic-dose anticoagulant therapy is unusual and should prompt the following assessments: (1) reevaluation of whether there truly was a recurrent VTE; (2) evaluation of compliance...
with anticoagulant therapy; and (3) consideration of an underlying malignancy.

CHEST has been developing and publishing guidelines for the treatment of DVT and PE, collectively referred to as VTE, for more than 30 years. CHEST published the last (9th) edition of these guidelines in February 2012 (AT9). Since then, a substantial amount of new evidence relating to the treatment of VTE has been published, particularly in relation the use of non-vitamin K oral anticoagulants (NOACs). Moreover, several VTE treatment questions that were not addressed in the last edition have been highlighted. This article focuses on new developments and ongoing controversies in the treatment of VTE, updating recommendations for 12 topics that were included in AT9, and providing recommendations for 3 new topics. The target users of this guideline are clinicians.

Methods

Composition and Selection of Topic Panel Members

The Guidelines Oversight Committee (GOC) at CHEST appointed the editor for the guideline update. Then, the editor nominated the project executive committee, the chair, and the remaining panelists (see Acknowledgments section). The GOC approved all panelists after review of their qualifications and conflict of interest (COI) disclosures. The 15 panelists include general internists, thrombosis specialists, pulmonologists, hematologists, and methodologists.

Throughout guideline development, panelists were required to disclose any potential financial or intellectual conflicts of interest by topic. Financial and intellectual conflicts of interest were classified as primary (more serious) or secondary (less serious) (e-Table 1). Panelists with primary COIs were required to abstain from voting on related topic areas, but could participate in discussions provided they refrained from strong advocacy.

Selection of Topics and Key Questions

First, we listed all of the topic areas from AT9 and added potential new topics proposed by the panel members. Next, all panel members voted on whether each topic should be included in the update. Finally, the full panel reviewed the results of the vote and decided on the final list. The panel selected a total of 15 topics: 12 “update topics” from AT9 and 3 “new topics.” For each topic, we developed standardized questions in the Population, Intervention, Comparator, Outcome format (e-Table 2).

Systematic Search

Systematic methods were used to search for evidence for each question. When available, the National Library of Medicine’s medical subject headings keyword nomenclature was used. We searched MEDLINE via PubMed for original studies and the Cochrane Library for systematic reviews. For update topics, we searched the literature from January 2005 to July 2014. For new topics, we searched the literature from 1946 (Medline inception) to July 2014. All searches were limited to English-language publications. We augmented searches by checking reference lists of published articles and personal files, and with ongoing surveillance of the literature by panel members (e-Figures 1-4).

When we identified systematic reviews, we assessed their quality according to the Assessment of Multiple Systematic Reviews tool. We used those that were of highest quality and up to date as the source of evidence. In the absence of a satisfactory systematic review, we did our own evidence synthesis using the primary studies identified in AT9 and in the updated search. If the panel judged that the identified randomized controlled trials (RCTs) were inadequate, we expanded the search to include prospective cohort studies.

Study Selection, Data Abstraction, and Data Analysis

The criteria for selecting the evidence were based on the Population, Intervention, Comparator, Outcome elements of the standardized questions and the study design (e-Table 2). We followed standard processes (duplicate independent work with agreement checking and disagreement resolution) for title and abstract screening, full text screening, data abstraction, and risk of bias assessment. We abstracted data on the characteristics of: study design, participants, intervention, control, outcomes, funding, and COI. We assessed risk of bias using the Cochrane Risk of Bias Tool in randomized trials and an adapted tool for observational studies (e-Table 3).

When existing systematic reviews were not available or were inadequate, we performed meta-analyses when appropriate. For each outcome of interest, we calculated the risk ratios of individual studies then pooled them and assessed statistical heterogeneity using the I² statistic. We used a fixed-effects model when pooling data from two trials, or when one of the included trials was large relative to the others. Otherwise, we used a random-effects model. We used Review Manager software (version 5.2) to perform the meta-analyses and construct forest plots. We calculated absolute effects by applying pooled relative risks to baseline risks, ideally estimated from valid prognostic observational data or, in the absence of the latter, from control group risks. When credible data from prognostic observational studies were not available, we used risk estimates from control groups of RCTs included in the meta-analyses (e-Figures 5 and 6).

Assessing Quality of Evidence

Based on the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) approach, quality of evidence (also known as certainty of evidence) is defined as the extent to which our confidence in the effect estimate is adequate to support a recommendation. The quality of evidence is categorized as high (A level), moderate (B level), or low (includes very low) (C level). The rating of the quality of evidence reflects the strengths and limitations of the body of evidence and was based on the study design, risk of bias, imprecision, inconsistency of results, and likelihood of publication bias, in addition to factors specific to observational studies. Using GRADEpro software (version 3.6), we generated tables to summarize the judgments of the quality of the evidence and the relative and absolute effects. The GRADE tables include Summary of Findings tables presented in the main text, and a more detailed version called Evidence Profiles presented in the online supplement. The evidence profiles also explicitly link recommendations to the supporting evidence.

Drafting of Recommendations

Following the GRADE approach, the strength of a recommendation is defined as the extent to which we can be confident that the desirable effects of an intervention outweigh its undesirable effects. The strength of recommendation was categorized as strong (grade 1) or...
Choice of Long-Term (First 3 Months) and Extended (No Scheduled Stop Date) Anticoagulant

Summary of the Evidence

Phases of Anticoagulant Therapy for VTE: The need for anticoagulant therapy in patients with proximal DVT or PE is presented in AT9. The minimum duration of anticoagulant therapy for DVT or PE is usually 3 months; this period of treatment is referred to as "long-term therapy." A decision to treat patients for longer than 3 months, which we refer to as "extended anticoagulant therapy," usually implies that anticoagulant therapy will be continued indefinitely.

1. In patients with proximal DVT or pulmonary embolism (PE), we recommend long-term (3 months) anticoagulant therapy over no such therapy (Grade 1B).

Choice of Anticoagulant for Acute and Long-Term (First 3 Months) Therapy

AT9 recommendations on choice of anticoagulant therapy were based on comparisons of VKA with LMWH that were performed in the preceding two decades, and with two of the NOACs (dabigatran, rivaroxaban) that had recently been published. Although we judged that there was no convincing evidence that the efficacy of LMWH compared with VKA differed between VTE patients without and with cancer, there are, nevertheless, reasons to make different suggestions for the preferred anticoagulant in patients without and with cancer. We suggested VKA therapy over LMWH in patients without cancer for the following reasons: injections are burdensome; LMWH is expensive; there are low rates of recurrence with VKA in patients with VTE without cancer; and VKA may be as effective as LMWH in patients without cancer. We suggested LMWH over VKA in patients with cancer for the following reasons: there is moderate-quality evidence that LMWH was more effective than VKA in patients with cancer; there is a substantial rate of recurrent VTE in patients with VTE and cancer who are treated with VKA; it is often harder to keep patients with cancer who are on VKA in the therapeutic range; LMWH is reliable in patients who have difficulty with oral therapy (eg, vomiting); and LMWH is easier to withhold or adjust than VKA if invasive interventions are required or thrombocytopenia develops.

One new randomized trial compared LMWH (tinzaparin) with warfarin for the first 6 months of treatment in 900 cancer patients with VTE. The findings of this study are consistent with evidence in AT9 that LMWH is more effective than VKA for long-term treatment of VTE, but that there is no difference in major bleeding or death (Table 1, e-Table 4). Consequently, we still suggest VKA over LMWH in patients without cancer, and LMWH over VKA in patients with cancer, and we have not changed our assessment of the quality of evidence for either of these recommendations (Table 1, e-Table 4).

We suggested VKA therapy or LMWH over the NOACs in AT9 because only two randomized trials had compared a NOAC (dabigatran, rivaroxaban) with VKA therapy, and none had compared a NOAC with long-term LMWH. In addition, at that time, there was little experience using a NOAC for treatment of VTE and a scarcity of long-term follow-up data to support their efficacy and safety. Since then, four new
The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CATCH = Comparison of Acute Treatments in Cancer Haemostasis; GRADE = Grades of Recommendations, Assessment, Development, and Evaluation; LITE = Long-term Innovations in Treatment program; LMWH = low-molecular-weight heparin; RIETE = Registro Informatizado de Enfermedad Tromboembólica; RR = risk ratio; UFH = unfractionated heparin; VKA = vitamin K antagonist. GRADE Working Group grades of evidence: High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: We are very uncertain about the estimate.

### Table 1: Summary of Findings: LMWH vs VKA for Long-Term Treatment of VTE

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>3,396 (9 studies) 6 mo</td>
<td>@ @ @ @ Moderate because of risk of bias</td>
<td>RR 1.01 (0.89-1.14)</td>
<td>Noncancerd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 more per 1,000 (from 2 fewer to 2 more)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nonmetastatic Cancerd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 more per 1,000 (from 5 fewer to 6 more)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Metastatic Cancerd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>253 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 more per 1,000 (from 28 fewer to 35 more)</td>
</tr>
<tr>
<td><strong>Recurrent VTE</strong></td>
<td>3,627 (9 studies) 6 mo</td>
<td>@ @ @ Moderate because of risk of bias</td>
<td>RR 0.65 (0.51-0.83)</td>
<td>Lowf</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11 fewer per 1,000 (from 5 fewer to 15 fewer)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Moderatef</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>80 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28 fewer per 1000 (from 14 fewer to 39 fewer)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Highf</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>200 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70 fewer per 1,000 (from 34 fewer to 98 fewer)</td>
</tr>
<tr>
<td><strong>Major bleeding</strong></td>
<td>3,637 (9 studies) 6 mo</td>
<td>@ @ @ Moderate because of imprecision</td>
<td>RR 0.86 (0.56-1.32)</td>
<td>Lowf</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 fewer per 1,000 (from 9 fewer to 6 more)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Highf</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>80 per 1,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11 fewer per 1,000 (from 35 fewer to 26 more)</td>
</tr>
</tbody>
</table>

The relative effect (RR; 95% CI) of LMWH vs VKA was assessed, and compared, in the subgroup of trials that enrolled patients without (Hull et al174 [LITE], Lopez-Beret et al177) and with (Deitcher et al173 [ONCENOX], Hull et al174 [LITE], Lee et al170 [CLOT], Lee et al172 [CATCH], Lopez-Beret et al,177 Meyer et al178) cancer: Recurrent VTE: cancer RR 0.59 (0.44-0.78) vs no cancer RR 0.99 (0.89-1.11); P = .14 for subgroup difference. Major bleeding: cancer RR 0.96 (0.85-1.15) vs no cancer RR 0.75 (0.60-0.96); P = .10 for subgroup difference. All-cause mortality: cancer RR 1.00 (0.88-1.33) vs no cancer RR 1.67 (1.05-2.65); P = .10 for subgroup difference.

One study did not report deaths, which is unusual and could reflect selective reporting of outcomes.

Low corresponds to patients without cancer and patients with nonmetastatic cancer. High corresponds to patients with metastatic cancer. These control event rates were derived from the Comparative Registry of Patients with Venous Thromboembolism (RIETE) registry, an ongoing prospective registry of consecutive patients with acute VTE (Pandis oni et al183). None of the studies was blinded, whereas the diagnosis of recurrent VTE has a subjective component and there could be a lower threshold for diagnosis of recurrent VTE in VKA-treated patients because switching the treatment of such patients to LMWH is widely practiced. At the same time, there is reluctance to diagnose recurrent VTE in patients who are already on LMWH because there is no attractive alternative treatment option.

Risk of recurrent VTE: Low corresponds to patients with cancer (3% estimate taken from recent large RCTs of acute treatment), intermediate to patients with local or recently resected cancer (appears to be consistent with Prandoni [particularly if low risk is increased to 4%]), and high to patients with locally advanced or distant metastatic cancer (Pandis oni et al183).

CI includes both no effect and harm with LMWH.

95% CIs for the risk ratio for major bleeding includes a potentially clinically important increase or decrease with LMWH, and may also vary with the dose of LMWH used during the extended phase of therapy.

Risk of bleeding: Low corresponds to patients without risk factor for bleeding (ie, > 75 years, cancer, metastatic disease; chronic renal or hepatic failure; platelet count <80,000; requires antplatelet therapy; history of bleeding without a reversible cause) (Prandoni et al183, Byeth et al184). Bibliography: Deitcher et al173 [ONCENOX], Hull et al174 [LITE], Hull et al175 [LITE Home], Lee et al170 [CLOT], Lopez-Beret et al,177 Meyer et al,178 Romera et al,179 Lee et al172 [CATCH].
randomized trials have compared a NOAC (with\textsuperscript{23,24} or without\textsuperscript{25,26} initial heparin therapy) with VKA therapy (with initial heparin therapy) for the acute and long-term treatment of VTE.\textsuperscript{23-26} The findings of these studies have been analyzed in a number of systematic reviews,\textsuperscript{27,35} including a network meta-analysis.\textsuperscript{35} In addition, there is now extensive clinical experience using NOACs in patients with VTE and atrial fibrillation. For the comparison of each of the NOACs with VKA in the initial and long-term treatment of VTE, current evidence for efficacy is moderate or high quality, for safety (risk of bleeding) is moderate or high quality, and overall is moderate or high quality (Tables 2-5, e-Tables 5-8).

In the 10th Edition of the Antithrombotic Guideline (AT10), the panel’s overall assessment of the relative efficacy and risk of bleeding with different anticoagulant agents is that: (1) the risk reduction for recurrent VTE with all of the NOACs appears to be similar to the risk reduction with VKA,\textsuperscript{35} including in patients with cancer;\textsuperscript{36-39} (2) in patients with VTE and cancer, the risk reduction for recurrent VTE appears to be greater with LMWH than with VKA therapy;\textsuperscript{1,36,40} (3) the risk reduction for recurrent VTE with the NOACs compared to LMWH has not been assessed but, based on indirect comparisons, LMWH may be more effective that the NOACs in patients with VTE and cancer;\textsuperscript{45} (4) the risk reduction for recurrent VTE with different NOACs has not been directly compared but, based on indirect comparisons, appears to be similar to all of the NOACs;\textsuperscript{35} (5) the risk of bleeding with the NOACs, and particularly intracranial bleeding, is less with the NOACs than with VKA therapy;\textsuperscript{27,33,35,41,42} (6) based on patients with atrial fibrillation, GI bleeding may be higher with dabigatran, rivaroxaban, and edoxaban than with VKA therapy, although this has not been seen in patients with VTE;\textsuperscript{27,28,33,41,43} (7) based on indirect comparisons, the risk of bleeding may be lower with apixaban than with the other NOACs;\textsuperscript{5,44} and (8) despite the lack of specific reversal agents for the NOACs, the risk that a major bleed will be fatal appears to be no higher for the NOACs than for VKA therapy.\textsuperscript{33,34,44}\textsuperscript{4} Based on less bleeding with NOACs and greater convenience for patients and healthcare providers, we now suggest that a NOAC is used in preference to VKA for the initial and long-term treatment of VTE in patients without cancer. Factors that may influence which anticoagulant is chosen for initial and long-term treatment of VTE are summarized in Table 6. This decision is also expected to be sensitive to patient preferences. The order of our presentation of the NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) is based on the chronology of publication of the phase 3 trials in VTE treatment and should not be interpreted as the guideline panel’s order of preference for the use of these agents.

**TABLE 2** Summary of Findings: Dabigatran vs VKA for Long-Term Treatment of VTE\textsuperscript{a,b}

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies) Follow-up</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>5,107 (2 studies)</td>
<td>Moderate because of imprecision</td>
<td>RR 1.0 (0.67-1.50)\textsuperscript{d}</td>
<td>18 per 1,000\textsuperscript{d} (0 fewer per 1,000 (from 6 fewer to 9 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>5,107 (2 studies)</td>
<td>Moderate because of imprecision</td>
<td>RR 1.12 (0.77-1.62)\textsuperscript{d}</td>
<td>22 per 1,000\textsuperscript{d} (3 more per 1,000 (from 5 fewer to 13 more)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>5,107 (2 studies)</td>
<td>Moderate because of imprecision</td>
<td>RR 0.73 (0.48-1.10)\textsuperscript{d}</td>
<td>20 per 1,000\textsuperscript{d} (5 fewer per 1,000 (from 10 fewer to 2 more)</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Patients with acute VTE treated initially with LMWH or UFH.

\textsuperscript{b}Dabigatran 150 mg twice daily vs warfarin.

\textsuperscript{c}CI includes values suggesting no effect and values suggesting either benefit or harm.

\textsuperscript{d}Pooled analysis of Schulman et al\textsuperscript{20} (RE-COVER I) and Schulman et al\textsuperscript{24} (RE-COVER II) performed by Schulman et al.\textsuperscript{24}

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). RE-COVER I = Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism; RE-COVER II = Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symptomatic Venous Thromboembolism. See Table 1 legend for expansion of other abbreviations and GRADE Working Group grades of evidence.

\textsuperscript{e}All-cause mortality, recurrent VTE, major bleeding, and stroke. In the 10th Edition of the Antithrombotic Guideline (AT10), the panel’s overall assessment of the relative efficacy and risk of bleeding with different anticoagulant agents is that: (1) the risk reduction for recurrent VTE with all of the NOACs appears to be similar to the risk reduction with VKA,\textsuperscript{35} including in patients with cancer;\textsuperscript{36-39} (2) in patients with VTE and cancer, the risk reduction for recurrent VTE appears to be greater with LMWH than with VKA therapy;\textsuperscript{1,36,40} (3) the risk reduction for recurrent VTE with the NOACs compared to LMWH has not been assessed but, based on indirect comparisons, LMWH may be more effective that the NOACs in patients with VTE and cancer;\textsuperscript{45} (4) the risk reduction for recurrent VTE with different NOACs has not been directly compared but, based on indirect comparisons, appears to be similar to all of the NOACs;\textsuperscript{35} (5) the risk of bleeding with the NOACs, and particularly intracranial bleeding, is less with the NOACs than with VKA therapy;\textsuperscript{27,33,35,41,42} (6) based on patients with atrial fibrillation, GI bleeding may be higher with dabigatran, rivaroxaban, and edoxaban than with VKA therapy, although this has not been seen in patients with VTE;\textsuperscript{27,28,33,41,43} (7) based on indirect comparisons, the risk of bleeding may be lower with apixaban than with the other NOACs;\textsuperscript{5,44} and (8) despite the lack of specific reversal agents for the NOACs, the risk that a major bleed will be fatal appears to be no higher for the NOACs than for VKA therapy.\textsuperscript{33,34,44}\textsuperscript{4} Based on less bleeding with NOACs and greater convenience for patients and healthcare providers, we now suggest that a NOAC is used in preference to VKA for the initial and long-term treatment of VTE in patients without cancer. Factors that may influence which anticoagulant is chosen for initial and long-term treatment of VTE are summarized in Table 6. This decision is also expected to be sensitive to patient preferences. The order of our presentation of the NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) is based on the chronology of publication of the phase 3 trials in VTE treatment and should not be interpreted as the guideline panel’s order of preference for the use of these agents.
In patients with DVT of the leg or PE and no cancer, as long-term (first 3 months) anticoagulant therapy, we suggest dabigatran, rivaroxaban, apixaban, or edoxaban over vitamin K antagonist (VKA) therapy (all Grade 2B).

For patients with DVT of the leg or PE and no cancer who are not treated with dabigatran, rivaroxaban, apixaban, or edoxaban, we suggest VKA therapy over LMWH (Grade 2C).

Remarks: Initial parenteral anticoagulation is given before dabigatran and edoxaban, is not given before rivaroxaban and apixaban, and is overlapped with VKA therapy. See text for factors that influence choice of therapy.

In patients with VTE and cancer (“cancer-associated thrombosis”), as noted earlier in this section, we still suggest LMWH over VKA. In patients with VTE and cancer who are not treated with LMWH, we do not have

### Table 3

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies) Follow-up</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Risk with LMWH and VKA</th>
<th>Risk difference with Rivaroxaban (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>8,281 (2 studies) 3 mo</td>
<td>⬤ ⬤ ⬤ Moderate because of imprecision</td>
<td>RR 0.97 (0.73-1.27)</td>
<td>24 per 1,000</td>
<td>1 fewer per 1,000 (from 6 fewer to 6 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>8,281 (2 studies) 3 mo</td>
<td>⬤ ⬤ ⬤ Moderate because of imprecision</td>
<td>RR 0.90 (0.68-1.2)</td>
<td>23 per 1,000</td>
<td>2 fewer per 1,000 (from 7 fewer to 5 more)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>8,246 (2 studies) 3 mo</td>
<td>⬤ ⬤ ⬤ High</td>
<td>RR 0.55 (0.38-0.81)</td>
<td>17 per 1,000</td>
<td>8 fewer per 1,000 (from 3 fewer to 11 fewer)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). EINSTEIN-DVT = Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis; EINSTEIN-PE = Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism. See Table 1 legend for expansion of other abbreviations and GRADE Working Group grades of evidence.

*2. In patients with DVT of the leg or PE and no cancer, as long-term (first 3 months) anticoagulant therapy, we suggest dabigatran, rivaroxaban, apixaban, or edoxaban over vitamin K antagonist (VKA) therapy (all Grade 2B).

### Table 4

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Risk with LMWH and VKA</th>
<th>Risk Difference with Apixaban (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>5,365 (1 study)</td>
<td>⬤ ⬤ ⬤ Moderate because of imprecision</td>
<td>RR 0.79 (0.53-1.19)</td>
<td>19 per 1,000</td>
<td>4 fewer per 1,000 (from 9 fewer to 4 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>5,244 (1 study)</td>
<td>⬤ ⬤ ⬤ Moderate because of imprecision</td>
<td>RR 0.84 (0.6-1.18)</td>
<td>27 per 1,000</td>
<td>4 fewer per 1,000 (from 11 fewer to 5 more)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>5,365 (1 study)</td>
<td>⬤ ⬤ ⬤ High</td>
<td>RR 0.31 (0.17-0.55)</td>
<td>18 per 1,000</td>
<td>13 fewer per 1,000 (from 8 fewer to 15 fewer)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). AMPLIFY = Apixiban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy; PE = pulmonary embolism. See Table 1 legend for expansion of other abbreviations and GRADE Working Group grades of evidence.

* Apixaban 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 mo.

® Subcutaneous enoxaparin, followed by warfarin.

*CI includes values suggesting no effect and values suggesting either benefit or harm. Bibliography: Agnelli et al25 (AMPLIFY)
a preference for either an NOAC or VKA. In the absence of direct comparisons between NOACs, and no convincing indirect evidence that one NOAC is superior to another, we do not have a preference for one NOAC over another NOAC. Factors that may influence which anticoagulant is chosen for initial and long-term treatment of VTE are summarized in Table 6. This decision is also expected to be sensitive to patient preferences.

3. In patients with DVT of the leg or PE and cancer (“cancer-associated thrombosis”), as long-term (first 3 months) anticoagulant therapy, we suggest LMWH over VKA therapy (Grade 2C), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C), or edoxaban (Grade 2C).

Remarks: Initial parenteral anticoagulation is given before dabigatran and edoxaban, is not given before rivaroxaban and apixaban, and is overlapped with VKA therapy. See text for factors that influence choice of therapy.

Choice of anticoagulant for extended therapy (after 3 months and no scheduled stop date)

When AT9 was written, other than a comparison of low- and standard-intensity anticoagulant therapy, there were no comparisons of different types of extended therapy. Since AT9, dabigatran has been compared with VKA therapy for extended treatment of VTE and found to be similarly effective but associated with less bleeding (Table 7, e-Table 9).47 Extended treatment with dabigatran, rivaroxaban21 and apixaban48 markedly reduces recurrent VTE without being associated with much bleeding (Tables 8-10, e-Tables 10-12).49,50 These studies provide moderate quality evidence that dabigatran is as effective and as safe as VKA for extended treatment of VTE (Table 7, e-Table 9) and provide moderate quality evidence that each of the NOACs are effective at preventing recurrent VTE without being associated with a high risk of bleeding (Tables 8-10, e-Tables 10-12).

In AT9, we suggested that if a decision was made to use extended treatment of VTE, the same anticoagulant should be used as was used for the initial treatment period. Our intention then was to indicate that there was no obligation to switch from one anticoagulant to a different one after 3 or 6 months of treatment (eg, from LMWH to VKA in patients with VTE and cancer). We have revised the wording of this recommendation to make it clearer that we neither encourage nor discourage use of the same anticoagulant for initial and extended therapy.

Although we anticipate that the anticoagulant that was used for initial treatment will often also be used for the extended therapy, if there are reasons to change the type of anticoagulant, this should be done. We also note that whereas apixaban 5 mg twice daily is used for long-term treatment, apixaban 2.5 mg twice daily is used for extended therapy.28

---

**TABLE 5** Summary of Findings: Edoxaban vs VKA for Acute and Long-Term Treatment of VTE

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>8,240 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>RR 1.05 (0.82-1.33)</td>
<td>31 per 1,000^d 2 more per 1,000 (from 6 fewer to 10 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>8,240 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>RR 0.83 (0.57-1.21)</td>
<td>35 per 1,000 6 fewer per 1,000 (from 15 fewer to 7 more)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>8,240 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>RR 0.85 (0.6-1.21)</td>
<td>16 per 1,000 2 fewer per 1,000 (from 6 fewer to 3 more)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence.

* Patients with acute VTE who had initially received heparin.
^ Edoxaban 60 mg once daily, or 30 mg once daily if patients with creatinine clearance of 30 to 50 mL/min or a body weight below 60 kg.
^ CI includes values suggesting no effect and values suggesting either benefit or harm.
^ Death, with PE not ruled out. Bibliography: Buller et al23 (Hokusai-VTE study)
In patients with DVT of the leg or PE who receive extended therapy, we suggest that there is no need to change the choice of anticoagulant after the first 3 months (Grade 2C).

Remarks: It may be appropriate for the choice of anticoagulant to change in response to changes in the patient’s circumstances or preferences during the long-term or extended phases of treatment.

Duration of Anticoagulant Therapy

Summary of the Evidence

AT9 recommendations on how long VTE should be treated were based on comparisons of four durations of treatment: (1) 4 or 6 weeks; (2) 3 months; (3) longer than 3 months but still a time-limited course of therapy (usually 6 or 12 months); or (4) extended (also termed “indefinite”; no scheduled stopping date) therapy. These four options were assessed in four subgroups of VTE patients with different estimated risks of recurrence after stopping anticoagulant therapy: (1) VTE provoked by surgery (a major transient risk factor; 3% recurrence at 5 years); (2) VTE provoked by a nonsurgical transient risk factor (eg, estrogen therapy, pregnancy, leg injury, flight of >8 h; 15% recurrence at 5 years); (3) unprovoked (also termed “idiopathic”) VTE; not meeting criteria for provoked by a transient risk factor or by cancer (30% recurrence at 5 years); and (4) VTE associated with cancer (also termed “cancer-associated thrombosis”; 15% annualized risk of recurrence; recurrence at 5 years not estimated because of high mortality from cancer). Recurrence risk was further stratified by estimating the risk of recurrence after: (1) an isolated distal DVT was half that after a proximal DVT or PE and (2) a second unprovoked

<table>
<thead>
<tr>
<th>TABLE 6</th>
<th>Factors That May Influence Which Anticoagulant Is Chosen for Initial and Long-Term Treatment of VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor</td>
<td>Preferred Anticoagulant</td>
</tr>
<tr>
<td>Cancer</td>
<td>LMWH</td>
</tr>
<tr>
<td>Parenteral therapy to be avoided</td>
<td>Rivaroxaban; apixaban</td>
</tr>
<tr>
<td>Once daily oral therapy preferred</td>
<td>Rivaroxaban; edoxaban; VKA</td>
</tr>
<tr>
<td>Liver disease and coagulopathy</td>
<td>LMWH</td>
</tr>
<tr>
<td>Renal disease and creatinine clearance &lt;30 mL/min</td>
<td>VKA</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>VKA, rivaroxaban, apixaban, edoxaban</td>
</tr>
<tr>
<td>Dyspepsia or history of GI bleeding</td>
<td>VKA, apixaban</td>
</tr>
<tr>
<td>Poor compliance</td>
<td>VKA</td>
</tr>
<tr>
<td>Thrombolytic therapy use</td>
<td>UFH infusion</td>
</tr>
<tr>
<td>Reversal agent needed</td>
<td>VKA, UFH</td>
</tr>
<tr>
<td>Pregnancy or pregnancy risk</td>
<td>LMWH</td>
</tr>
<tr>
<td>Cost, coverage, licensing</td>
<td>Varies among regions and with individual circumstances</td>
</tr>
</tbody>
</table>

INR = International Normalized Ratio; NOAC = non-vitamin K oral coagulant. See Table 1 legend for expansion of other abbreviations.
proximal DVT or PE was 50% higher (1.5-fold) than after a first unprovoked event. For the decision about whether to stop treatment at 3 months or to treat indefinitely (“extended treatment”), we categorized a patient’s risk of bleeding on anticoagulant therapy as low (no bleeding risk factors; 0.8% annualized risk of major bleeding), moderate (one bleeding risk factor; 1.6% annualized risk of major bleeding), or high (two or

### TABLE 7 | Summary of Findings: Dabigatran vs VKA for Extended Treatment of VTE

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>2,856 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>RR 0.89 (0.47-1.71)</td>
<td>13 per 1,000 1 fewer per 1,000 (from 7 fewer to 9 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>2,856 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>RR 1.44 (0.79-2.62)</td>
<td>13 per 1,000 6 more per 1,000 (from 3 fewer to 20 more)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>2,856 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>RR 0.52 (0.27-1.01)</td>
<td>18 per 1,000 8 fewer per 1,000 (from 13 fewer to 0 more)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). REMEDY = Secondary Prevention of Venous Thrombo Embolism. See Table 1 and 4 legends for expansion of other abbreviations and GRADE Working Group grades of evidence.

### TABLE 8 | Summary of Findings: Dabigatran vs Placebo for Extended Treatment of VTE

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>1,343 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>Not estimable e</td>
<td>...</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>1,343 (1 study)</td>
<td>High</td>
<td>RR 0.08 (0.02-0.25)</td>
<td>56 per 1,000 51 fewer per 1,000 (from 42 fewer to 55 fewer)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>1,343 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>Not estimable f</td>
<td>...</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). RESONATE = Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Exetilate in the Long Term Prevention of Recurrent Symptomatic VTE. See Table 1 and 4 legends for expansion of other abbreviations and GRADE Working Group grades of evidence.

---

**Notes:**
- proximal DVT or PE was 50% higher (1.5-fold) than after a first unprovoked event. For the decision about whether to stop treatment at 3 months or to treat indefinitely (“extended treatment”), we categorized a patient’s risk of bleeding on anticoagulant therapy as low (no bleeding risk factors; 0.8% annualized risk of major bleeding), moderate (one bleeding risk factor; 1.6% annualized risk of major bleeding), or high (two or
more bleeding risk factors; ≈6.5% annualized risk of major bleeding) (Table 11). A VKA targeted to an International Normalized Ratio (INR) of about 2.5 was the anticoagulant in all studies that compared different time-limited durations of therapy. We, therefore, assumed that VKA therapy was the anticoagulant when we were making our AT9 recommendations, including for the comparison of extended therapy with stopping treatment at 3 months.

### Comparison of Different Time-Limited Durations of Anticoagulation Since AT9: Two additional studies have compared two time-limited durations of anticoagulant therapy. In patients with a first unprovoked PE who had completed 6 months of VKA therapy (target INR 2.5), the Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial (PADIS) study randomized patients to

#### TABLE 9 | Summary of Findings: Rivaroxaban vs Placebo for Extended Treatment of VTE\(^{a,b}\)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>1,196 (1 study)</td>
<td>Moderate because of imprecision</td>
<td>RR 0.49 (0.04–5.43)</td>
<td>3 per 1,000 2 fewer per 1,000 (from 3 fewer to 15 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>1,196 (1 study)</td>
<td>High</td>
<td>RR 0.19 (0.09–0.4)</td>
<td>71 per 1000 57 fewer per 1,000 (from 42 fewer to 64 fewer)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>1,188 (1 study)</td>
<td>Moderate because of risk of bias</td>
<td>Not estimable(^d)</td>
<td>... ...</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence.

\(^a\)Patients who had completed 6 to 12 mo of treatment for VTE.

\(^b\)Rivaroxaban 20 mg daily or placebo, specific to the continued treatment study.

\(^c\)Includes values suggesting no effect and values suggesting either benefit or harm.

\(^d\)Event rate with rivaroxaban was 4/598 (0.67%); event rate with placebo was 0/590 (0%); anticipated absolute effect-risk difference with rivaroxaban is 4 more per 1,000 (from 1 less to 17 more). Bibliography: Bauersachs et al\(^{21}\) (EINSTEIN-Extension)

#### TABLE 10 | Summary of Findings: Apixaban vs Placebo for Extended Treatment of VTE\(^{a,b}\)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies) Follow-up</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>1,669 (1 study) 12 mo</td>
<td>Moderate because of imprecision</td>
<td>RR 0.49 (0.2–1.22)</td>
<td>17 per 1,000 9 fewer per 1,000 (from 14 fewer to 4 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>1,669 (1 study) 12 mo</td>
<td>High</td>
<td>RR 0.19 (0.11–0.33)</td>
<td>88 per 1,000 71 fewer per 1,000 (from 59 fewer to 78 fewer)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>1,669 (1 study) 12 mo</td>
<td>Moderate because of imprecision</td>
<td>RR 0.49 (0.09–2.64)</td>
<td>5 per 1,000 2 fewer per 1,000 (from 4 fewer to 8 more)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence.

\(^a\)Patients with VTE who had completed 6 to 12 mo of anticoagulation therapy.

\(^b\)Apixaban 2.5 mg twice-daily dose vs placebo.

\(^c\)Significantly wide CIs, including appreciable benefit/harm and no effect line.

\(^d\)Low number of events. Bibliography: Agnelli et al\(^{48}\) (AMPLIFY-EXT)
### TABLE 11 | Risk Factors for Bleeding with Anticoagulant Therapy and Estimated Risk of Major Bleeding in Low-, Moderate-, and High-Risk categoriesa

<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>Estimated Absolute Risk of Major Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low Riskc (0 Risk Factors)</td>
</tr>
<tr>
<td>Anticoagulation 0-3 moe</td>
<td></td>
</tr>
<tr>
<td>Baseline risk (%)</td>
<td>0.6</td>
</tr>
<tr>
<td>Increased risk (%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Total risk (%)</td>
<td>1.69</td>
</tr>
<tr>
<td>Anticoagulation after first 3 mo</td>
<td></td>
</tr>
<tr>
<td>Baseline risk (%)</td>
<td>0.33</td>
</tr>
<tr>
<td>Increased risk (%)</td>
<td>0.5</td>
</tr>
<tr>
<td>Total risk (%)</td>
<td>0.81</td>
</tr>
</tbody>
</table>

**AT9 = 9th Edition of the Antithrombotic Guideline.**

aFrom AT9. Since AT9, references for bleeding with individual factors have been added; nonsteroidal anti-inflammatory drug has been added as a risk factor; a systematic review has described the risk in VTE trial patients who were randomized to no antithrombotic therapy; and several recent publications have compared clinical prediction rules for bleeding in various populations.

bMost studies assessed risk factors for bleeding in patients who were on VKA therapy. The risk of bleeding with different anticoagulants is not addressed in this table. The increase in bleeding associated with a risk factor will vary with: (1) severity of the risk factor (eg, location and extent of metastatic disease; platelet count); (2) temporal relationships (eg, interval from surgery or a previous bleeding episode); and (3) how effectively a previous cause of bleeding was corrected (eg, upper GI bleeding).

Important for parenteral anticoagulation (eg, first 10 d), but less important for long-term or extended anticoagulation.

bAlthough there is evidence that risk of bleeding increases with the prevalence of risk factors, the categorization scheme suggested here has not been validated. Furthermore, a single risk factor, when severe, will result in a high risk of bleeding (eg, major surgery within the past 2 d; severe thrombocytopenia).

Comparing with low-risk patients, moderate-risk patients are assumed to have a twofold risk and high-risk patients are assumed to have an eightfold risk of major bleeding.

We estimate that anticoagulation is associated with a 2.6-fold increase in major bleeding based on comparison of extended anticoagulation with no extended anticoagulation (Table 6 in AT9). The relative risk of major bleeding during the first 3 mo of therapy may be greater that during extended VKA therapy because: (1) the intensity of anticoagulation with initial parenteral therapy may be greater that with VKA therapy; (2) anticoagulant control will be less stable during the first 3 mo; and (3) predispositions to anticoagulant-induced bleeding may be uncovered during the first 3 mo of therapy. However, studies of patients with acute coronary syndromes do not suggest a higher than 2.6 relative risk of major bleeding with parenteral anticoagulation (eg, UFH, LMWH) compared with controls.

1.8% corresponds to the average of major bleeding with initial UFH or LMWH therapy followed by VKA therapy (Table 7 in AT9). We estimated baseline risk by assuming a 2.5 relative risk of major bleeding with anticoagulation (footnote f).

Consistent with frequency of major bleeding observed by Hull in “high-risk” patients.

Our estimated baseline risk of major bleeding for low-risk patients (and adjusted up for moderate- and high-risk groups as per footnote e).

Consistent with frequency of major bleeding during prospective studies of extended anticoagulation for VTE (Table 6 in AT9).

Another 18 months of treatment or to placebo, and then followed both groups of patients for an additional 24 months after study drug was stopped (Table 12, e-Table 13). The study’s findings were consistent with our recommendations in AT9; the additional 18 months of VKA was very effective at preventing recurrent VTE but, once anticoagulation was stopped, the risk of recurrent VTE was the same in those who had been treated for 6 or for 24 months. This new information has not increased the quality of evidence for comparison of a longer vs a shorter, time-limited course of anticoagulation in patients without cancer.

In patients with a first proximal DVT or PE and active cancer who had residual DVT on US imaging after completing 6 months of LMWH therapy, the Cancer-Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study randomized patients to another 6 months of LMWH or to stop therapy and followed patients for 12 months after they stopped LMWH. The additional 6 months of LMWH reduced recurrent VTE but, once anticoagulation was stopped, the risk of recurrent VTE was the same in those who had
been treated for 6 or for 12 months. In the same study, all patients without residual DVT after 6 months of LMWH stopped therapy and had a low risk of recurrence during the next year (three episodes in 91 patients). This study’s findings have not changed our recommendations for treatment of VTE in patients with cancer.

**Evaluations of Extended Anticoagulant Therapy Since AT9:** When AT9 was written, extended treatment of VTE with VKA therapy had been evaluated in six studies (mostly patients with unprovoked proximal DVT or PE \(^{46,61-64}\) or a second episode of VTE \(^{65}\)), and with an NOAC (rivaroxaban vs placebo) in one study of heterogeneous patients.\(^{21}\) Since AT9, no studies have compared extended VKA therapy with stopping anticoagulants, although the large reduction in recurrent VTE with 18 additional months of VKA therapy compared with placebo (ie, before study drug was stopped) in the PADIS study\(^{60}\) supports AT9 estimates for the efficacy of extended VKA therapy.

Since AT9, two additional studies have compared extended NOAC therapy (dabigatran,\(^{47}\) apixaban\(^{48}\)) with stopping treatment (ie, placebo). These two studies, and the previous study that evaluated extended treatment with rivaroxaban, found that extended therapy with these three NOAC regimens reduced recurrent VTE by at least 80% and was associated with a modest risk of bleeding (Tables 8-10, e-Tables 10-12).\(^{19}\) These three studies, however, enrolled heterogeneous populations of patients (ie, not confined to unprovoked VTE) and only followed patients for 6 to 12 months, which limits the implications of their findings in relationship to extended therapy.

When considering the risks and benefits of extended anticoagulation in this update, the AT10 panel decided

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies) Follow-up</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Risk with No Extended Use</th>
<th>Risk Difference with Extended Use (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality</strong></td>
<td>1,736 (7 studies) 1-3 y</td>
<td>⬈ ⬈ ⬈ ⬈⃝ Moderate (^{&lt;5,6}) because of imprecision</td>
<td>RR 1.39 (0.91-2.12)</td>
<td>41 per 1,000</td>
<td>16 more per 1,000 (from 4 fewer to 46 more)</td>
</tr>
<tr>
<td><strong>Recurrent VTE</strong></td>
<td>2,466 (8 studies) 1-3 y</td>
<td>⬈ ⬈ ⬈ ⬈⃝ Moderate (^{&lt;5,6}) because of imprecision</td>
<td>RR 0.88 (0.71-1.09)</td>
<td>128 per 1,000</td>
<td>18 fewer per 1,000 (from 40 fewer to 8 more)</td>
</tr>
<tr>
<td><strong>Major bleeding</strong></td>
<td>2,466 (8 studies) 1-3 y</td>
<td>⬈ ⬈ ⬈ ⬈⃝ Moderate (^{&lt;5,6}) because of imprecision</td>
<td>RR 1.78 (0.95-3.34)</td>
<td>12 per 1,000</td>
<td>9 more per 1,000 (from 1 fewer to 27 more)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). DACUS = Warfarin Optimal Duration Italian Pulmonary Embolism; DOTAVK = Durée Optimale du Traitement AntiVitamines K; WODIT-DVT = Warfarin Optimal Duration Italian Deep Vein Thrombosis; WODIT-PE = Warfarin Optimal Duration Italian Pulmonary Embolism. See Table 1, 4, and 6 legends for expansion of other abbreviations and GRADE Working Group grades of evidence.\(^{b}\) Studies vary in follow-up duration (10 mo-3 y) and in duration of time-limited VKA (3-6 mo).\(^{b}\) VKA as NOACs are not included.\(^{b}\) Timing of randomization relative to the start of treatment and length of treatment varied across studies: Pinede et al\(^{223}\) and Campbell et al\(^{222}\) randomized at diagnosis; and Agnelli et al\(^{224}\), Eischer et al\(^{227}\) and Couturaud et al\(^{60}\) randomized after the initial 3 mo (Agnelli et al\(^{225}\) or 6 mo (Eischer et al\(^{227}\); Couturaud et al\(^{60}\)) of treatment to stop or continued treatment. The longer duration of treatment was 6 mo in Agnelli et al\(^{224}\) (provoked PE) and Pinede et al\(^{223}\), 12 mo in Agnelli et al\(^{224,225}\) (unprovoked DVT; unprovoked PE), 24 mo in Couturaud et al\(^{60}\) and 30 mo in Eischer et al\(^{227}\). Generally, study design was strong. No study stopped early for benefit; 3 stopped early because of slow recruitment (Campbell et al\(^{222}\), Pinede et al\(^{223}\), Eischer et al\(^{227}\); Couturaud et al\(^{60}\)) and 1 because of lack of benefit (Agnelli et al\(^{224}\)). In 1 study (Campbell et al\(^{222}\)), 20% of VTE outcomes were not objectively confirmed. Patients and caregivers were blinded in Couturaud et al\(^{60}\) but none of the other studies was. Adjudicators of outcomes were blinded in all but 1 study (Campbell et al\(^{222}\)). All studies used effective randomization concealment, intention-to-treat analysis, and a low unexplained dropout frequency.\(^{b}\) Study populations varied across studies: Pinede et al\(^{223}\) enrolled provoked and unprovoked proximal DVT and PE; Campbell et al\(^{222}\) enrolled provoked and unprovoked isolated distal DVT, proximal DVT, and PE; Agnelli et al\(^{224}\) had separate randomizations for provoked PE (3 vs 6 mo) and unprovoked (3 vs 12 mo); Agnelli et al\(^{225}\) enrolled unprovoked proximal DVT; Eischer et al\(^{227}\) enrolled unprovoked isolated DVT, proximal DVT, and PE with high levels of factor VIII; and Couturaud et al\(^{60}\) enrolled unprovoked PE.\(^{5}\) CIs include both values suggesting no effect and values suggesting either benefit or harm. Bibliography: Campbell et al\(^{222}\), Pinede et al\(^{223}\) (DOTAVK), Agnelli et al\(^{224}\) (WODIT-PE Provoked and Unprovoked), Agnelli et al\(^{225}\) (WODIT-DVT), Couturaud et al\(^{60}\) (PADIS-PE), Siragusa et al\(^{226}\) (DACUS), Eischer et al\(^{227}\) (AUREC-FVIII).
to use the same estimates for the reduction in recurrent VTE and the increase in bleeding with anticoagulation that we used in AT9, and that were based on VKA therapy. Our reasoning was: (1) VKA is still widely used for extended treatment of VTE; (2) we felt that there was not enough evidence of differences in efficacy and bleeding during extended therapy to justify separate recommendations for NOACs, either as a group or as individual agents; and (3) our recommendations about whether or not to use extended therapy were not sensitive to assuming that there was a one-third reduction in bleeding with extended therapy compared with the estimated risk of bleeding with extended therapy that are shown in Table 11 and were used in AT9 (eg, with a NOAC compared with VKA)\textsuperscript{27,31,35,49} (the only recommendation to change would be a strong instead of a weak recommendation in favor of extended therapy in patients with a second unprovoked VTE who had a moderate risk of bleeding).

Better Selection of Patients for Extended VTE Therapy: The most common and difficult decision about whether to stop anticoagulants after a time-limited course or to use extended therapy is in patients with a first unprovoked proximal DVT or PE without a high risk of bleeding. In this subgroup of patients, patient sex and D-dimer level measured about 1 month after stopping anticoagulant therapy can help to further stratify the risk of recurrent VTE.\textsuperscript{66-69} Men have about a 75% higher (1.75-fold) risk of recurrence compared with women, whereas patients with a positive D-dimer result have about double the risk of recurrence compared with those with a negative D-dimer, and the predictive value of these two factors appears to be additive. The risk of recurrence in women with a negative posttreatment D-dimer appears to be similar to the risk that we have estimated for patients with a proximal DVT or PE that was provoked by a minor transient risk factor (approximately 15% recurrence at 5 years); consequently, the argument for extended anticoagulation in these women is not strong, suggesting that D-dimer testing will often influence a woman’s decision. The risk of recurrence in men with a negative D-dimer is not much less than the overall risk of recurrence that we have estimated for patients with an unprovoked proximal DVT or PE (approximately 25% compared with approximately 30% recurrence at 5 years); consequently, the argument for extended anticoagulation in these men is still substantial, suggesting that D-dimer testing will often not influence a male’s decision. Because there is still uncertainty about how to use D-dimer testing and a patient’s sex to make decisions about extended therapy in patients with a first unprovoked VTE, we have not made recommendations based on these factors.

Revised Recommendations: These are unchanged from AT9 with one minor exception. A qualifying remark has been added to the recommendation that suggests extended therapy over stopping treatment at 3 months in patients with a first unprovoked proximal DVT or PE and a low or moderate risk of bleeding: this remark notes that patient sex and D-dimer level measured a month after stopping anticoagulant therapy may influence this treatment decision. If it becomes clear that, during the extended phase of treatment, there are important differences in the risk of recurrence or bleeding with the different anticoagulant agents, agent-specific recommendations for extended therapy may become justified.

5. In patients with a proximal DVT of the leg or PE provoked by surgery, we recommend treatment with anticoagulation for 3 months over (i) treatment of a shorter period (Grade 1B), (ii) treatment of a longer, time-limited period (eg, 6, 12, or 24 months) (Grade 1B), or (iii) extended therapy (no scheduled stop date) (Grade 1B).

6. In patients with a proximal DVT of the leg or PE provoked by a nonsurgical transient risk factor, we recommend treatment with anticoagulation for 3 months over (i) treatment of a shorter period (Grade 1B) and (ii) treatment of a longer time-limited period (eg, 6, 12, or 24 months) (Grade 1B). We suggest treatment with anticoagulation for 3 months over extended therapy if there is a low or moderate bleeding risk (Grade 2B), and recommend treatment for 3 months over extended therapy if there is a high risk of bleeding (Grade 1B).

Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually).

7. In patients with an isolated distal DVT of the leg provoked by surgery or by a nonsurgical transient risk factor, we suggest treatment with anticoagulation for 3 months over treatment of a shorter period (Grade 2C); we recommend treatment with anticoagulation for 3 months over treatment of a longer, time-limited period (eg, 6, 12, or 24 months) (Grade 1B); and we recommend treatment with anticoagulation for 3 months over extended therapy (no scheduled stop date) (Grade 1B).
Remarks: Duration of treatment of patients with isolated distal DVT refers to patients in whom a decision has been made to treat with anticoagulant therapy; however, it is anticipated that not all patients who are diagnosed with isolated distal DVT will be prescribed anticoagulants.

8. In patients with an unprovoked DVT of the leg (isolated distal or proximal) or PE, we recommend treatment with anticoagulation for at least 3 months over treatment of a shorter duration (Grade 1B), and we recommend treatment with anticoagulation for 3 months over treatment of a longer, time-limited period (eg, 6, 12, or 24 months) (Grade 1B).

Remarks: After 3 months of treatment, patients with unprovoked DVT of the leg or PE should be evaluated for the risk-benefit ratio of extended therapy. Duration of treatment of patients with isolated distal DVT refers to patients in whom a decision has been made to treat with anticoagulant therapy; however, it is anticipated that not all patients who are diagnosed with isolated distal DVT will be prescribed anticoagulants.

9. In patients with a first VTE that is an unprovoked proximal DVT of the leg or PE and who have a (i) low or moderate bleeding risk (see text), we suggest extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 2B), and a (ii) high bleeding risk (see text), we recommend 3 months of anticoagulant therapy over extended therapy (no scheduled stop date) (Grade 1B).

Remarks: Patient sex and D-dimer level measured a month after stopping anticoagulant therapy may influence the decision to stop or extend anticoagulant therapy (see text). In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually).

10. In patients with a second unprovoked VTE and who have a (i) low bleeding risk (see text), we recommend extended anticoagulant therapy (no scheduled stop date) over 3 months (Grade 1B); (ii) moderate bleeding risk (see text), we suggest extended anticoagulant therapy over 3 months of therapy (Grade 2B); or (iii) high bleeding risk (see text), we suggest 3 months of anticoagulant therapy over extended therapy (no scheduled stop date) (Grade 2B).

Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually).

Aspirin for Extended Treatment of VTE

Summary of the Evidence

AT9 did not address if there was a role for aspirin, or antiplatelet therapy generally, in the treatment of VTE. Since then, two randomized trials have compared aspirin with placebo for the prevention of recurrent VTE in patients with a first unprovoked proximal DVT or PE who have completed 3 to 18 months of anticoagulant therapy.70-72 These trials provide moderate-quality evidence that extended aspirin therapy reduces recurrent VTE by about one-third. In these trials, the benefits of aspirin outweighed the increase in bleeding, which was not statistically significant (Table 13, e-Table 14). The two trials enrolled patients with a first unprovoked VTE who did not have an increased risk of bleeding; patients for whom these guidelines have suggested extended anticoagulant therapy. Extended anticoagulant therapy is expected to reduce recurrent VTE by more than 80% and extended NOAC therapy may be associated with the same risk of bleeding as aspirin.49,50 If patients with a first unprovoked VTE decline extended anticoagulant therapy because they have risk factors for bleeding or because they have a lower than average risk of recurrence, the net benefit of aspirin therapy is expected to be less than in the two trials that evaluated aspirin for extended treatment of VTE.

Based on indirect comparisons, we expect the net benefit of extended anticoagulant therapy in patients with unprovoked VTE to be substantially greater than the benefits of extended aspirin therapy.49 Consequently, we do not consider aspirin a reasonable alternative to anticoagulant therapy in patients who want extended therapy. However, if a patient has decided to stop
anticoagulants, prevention of recurrent VTE is one of the benefits of aspirin (may also include reductions in arterial thrombosis and colon cancer) that needs to be balanced against aspirin’s risk of bleeding and inconvenience. Use of aspirin should also be reevaluated when patients stop anticoagulant therapy because aspirin may have been stopped when anticoagulants were started (Table 13, e-Table 14).

*12. In patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin, we suggest aspirin over no aspirin to prevent recurrent VTE (Grade 2B).

Remarks: Because aspirin is expected to be much less effective at preventing recurrent VTE than anticoagulants, we do not consider aspirin a reasonable alternative to anticoagulant therapy in patients who want extended therapy. However, if a patient has decided to stop anticoagulants, prevention of recurrent VTE is one of the benefits of aspirin that needs to be balanced against aspirin’s risk of bleeding and inconvenience. Use of aspirin should also be reevaluated when patients stop anticoagulant therapy because aspirin may have been stopped when anticoagulants were started.

Whether and How to Prescribe Anticoagulants to Patients With Isolated Distal DVT

Summary of the Evidence

AT9 discouraged routine whole-leg US examinations (ie, including the distal veins) in patients with suspected DVT, thereby reducing how often isolated distal DVT is diagnosed.1,73 The rationale for not routinely examining the distal veins in patients who have had proximal DVT excluded is that: (1) other assessment may already indicate that isolated distal DVT is either unlikely to be present or unlikely to cause complications if it is present (eg, low clinical probability of DVT, D-dimer is negative); (2) if these conditions are not met, a repeat US examination of the proximal veins can be done after a week to detect possible DVT extension and the need for treatment; and (3) false-positive findings for DVT occur more often with US examinations of the distal compared with the proximal veins.1,73,74

If the calf veins are imaged (usually with US) and isolated distal DVT is diagnosed, there are two management options: (1) treat patients with anticoagulant therapy or (2) do not treat patients with anticoagulant therapy unless extension of their DVT is detected on a follow-up US examination (eg, after 1 and

### TABLE 13  Summary of Findings: Aspirin vs Placebo for Extended Treatment of VTE

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies) Follow-up</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>1,224 (2 studies) Up to 4 y</td>
<td>Low because of imprecision</td>
<td>HR 0.82 (0.45-1.52)</td>
<td>Moderate-Risk Population^2</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>1,224 (2 studies) Up to 4 y</td>
<td>Moderate because of imprecision</td>
<td>HR 0.65 (0.49-0.86)</td>
<td>184 per 1,000 (from 3 fewer to 89 fewer)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>1,224 (2 studies) Up to 4 y</td>
<td>Moderate because of imprecision</td>
<td>HR 1.31 (0.48-3.53)</td>
<td>12 per 1,000 (from 6 fewer to 29 more)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ASPIRE = Aspirin to Prevent Recurrent Venous Thromboembolism; HR = hazard ratio; INSPIRE = International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism; WARFASA = Aspirin for the Prevention of Recurrent Venous Thromboembolism (the Warfarin and Aspirin) study. See Table 1 legend for expansion of other abbreviations and GRADE Working Group grades of evidence.

^2The Brighton et al70 study was stopped early and included only one-third of the intended patients.

CI includes values suggesting no effect and values suggesting either benefit or harm.

Estimate based on Simes et al72 (INSPIRE) of synthesis of Brighton et al70 (ASPIRE) and Becattini et al71 (WARFASA).

Estimate taken from Douketis et al.228 Bibliography: Simes et al72 (INSPIRE)
2 weeks, or sooner if there is concern; there is no widely accepted protocol for surveillance US testing. Because about 15% of untreated isolated distal DVT are expected to subsequently extend into the popliteal vein and may cause PE, it is not acceptable to neither anticoagulate nor do surveillance to detect thrombus extension.\textsuperscript{1,76}\textsuperscript{-79}

In AT9, we judged that there was high-quality evidence that anticoagulant therapy was effective for the treatment of proximal DVT and PE, but uncertainty that the benefits of anticoagulation outweigh its risks in patients with isolated distal DVT because of their lower risk of progressive or recurrent VTE. We suggest the following as risk factors for extension of distal DVT that would favor anticoagulation over surveillance: (1) D-dimer is positive (particularly when markedly so without an alternative reason); (2) thrombosis is extensive (eg, >5 cm in length, involves multiple veins, >7 mm in maximum diameter); (3) thrombosis is close to the proximal veins; (4) there is no reversible provoking factor for DVT; (5) active cancer; (6) history of VTE; and (7) inpatient status.\textsuperscript{1,75-77,80-84} We consider thrombosis that is confined to the muscular veins of the calf (ie, soleus, gastrocnemius) to have a lower risk of extension than thrombosis that involves the axial (ie, true deep; peroneal, tibial) veins.\textsuperscript{76,81,85} Severe symptoms favor anticoagulation, a high risk for bleeding (Table 11) favors surveillance, and the decision to use anticoagulation or surveillance is expected to be sensitive to patient preferences. We anticipate that isolated distal DVT that are detected using a selective approach to whole-leg US will often satisfy criteria for initial anticoagulation, whereas distal DVT detected by routine whole-leg US often will not.

The updated literature search did not identify any new randomized trials that assessed management of patients with isolated distal DVT. Two new systematic reviews\textsuperscript{76,77} and a narrative review\textsuperscript{83} addressed treatment of isolated distal DVT. In addition to summarizing available data, consistent with AT9, they emphasize the limitations of available evidence. In the absence of substantive new evidence, the panel endorsed the AT9 recommendations without revision. The evidence supporting these recommendations remains low quality because it is not based on direct comparisons of the two management strategies, and ability to predict extension of distal DVT is limited.

13. In patients with acute isolated distal DVT of the leg and (i) without severe symptoms or risk factors for extension (see text), we suggest serial imaging of the deep veins for 2 weeks over anticoagulation (Grade 2C), and (ii) with severe symptoms or risk factors for extension (see text), we suggest anticoagulation over serial imaging of the deep veins (Grade 2C).

Remarks: Patients at high risk for bleeding are more likely to benefit from serial imaging. Patients who place a high value on avoiding the inconvenience of repeat imaging and a low value on the inconvenience of treatment and on the potential for bleeding are likely to choose initial anticoagulation over serial imaging.

14. In patients with acute, isolated, distal DVT of the leg who are managed with anticoagulation, we recommend using the same anticoagulation as for patients with acute proximal DVT (Grade 1B).

15. In patients with acute, isolated, distal DVT of the leg who are managed with serial imaging, we (i) recommend no anticoagulation if the thrombus does not extend (Grade 1B), (ii) suggest anticoagulation if the thrombus extends but remains confined to the distal veins (Grade 2C), and (iii) recommend anticoagulation if the thrombus extends into the proximal veins (Grade 1B).

CDT for Acute DVT of the Leg

Summary of the Evidence

At the time of AT9, there was one small randomized trial\textsuperscript{86} comparing the effect of CDT vs anticoagulant alone on development of PTS, and another larger randomized trial (Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis [CAVENT] Study) assessing short-term (eg, venous patency and bleeding) but not long-term (eg, PTS) outcomes.\textsuperscript{87,88} The CAVENT Study has since reported that CDT reduced PTS, did not alter quality of life, and appears to be cost-effective (Table 14, e-Table 15).\textsuperscript{89-92} A retrospective analysis found that CDT (3649 patients) was associated with an increase in transfusion (twofold), intracranial bleeding (threefold), PE (1.5-fold), and vena caval filter insertion (twofold); long-term outcomes and PTS were not reported.\textsuperscript{93} A single-center prospective registry found that US-assisted CDT in acute iliofemoral (87 patients) achieved high rates of venous patency, was rarely associated with bleeding, and that only 6% of patients had PTS at 1 year.\textsuperscript{94}

This new evidence has not led to a change in our recommendation for the use of CDT in patients with
DVT. Although the quality of the evidence has improved, the overall quality is still low because of very serious imprecision. Unchanged from AT9, we propose that the patients who are most likely to benefit from CDT have iliofemoral DVT, symptoms for <14 days, good functional status, life expectancy of ≥1 year, and a low risk of bleeding (Tables 14 and 15, e-Table 15). Because the balance of risks and benefits with CDT is

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies) Follow-up</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>209 (1 study) 3 mo</td>
<td>Low</td>
<td>RR 0.43 (0.08-2.16)</td>
<td>46 per 1,000 (from 43 fewer to 54 more)</td>
</tr>
<tr>
<td>Recurrent VTE</td>
<td>189 (1 study) 3 mo</td>
<td>Low</td>
<td>RR 0.61 (0.3-1.25)</td>
<td>Moderate-Risk Population</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>224 (2 studies) 3 mo</td>
<td>Low</td>
<td>RR 7.69 (0.4-146.9)</td>
<td>Moderate-Risk Population</td>
</tr>
<tr>
<td>PTS</td>
<td>189 (1 study) 2 y</td>
<td>Moderate</td>
<td>RR 0.74 (0.55-1)</td>
<td>29 per 1,000 (from 17 fewer to 1000 more)</td>
</tr>
<tr>
<td>Patency</td>
<td>189 (1 study) 6 mo</td>
<td>Moderate</td>
<td>RR 1.42 (1.09-1.85)</td>
<td>455 per 1,000 (from 41 more to 386 more)</td>
</tr>
<tr>
<td>QoL</td>
<td>189 (1 study) 24 mo</td>
<td>Moderate</td>
<td>RR (95% CI)</td>
<td>The mean quality of life in the intervention groups was 0.2 higher (2.8 lower to 3 higher)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CAVENT = Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis; EQ-5D = EuroQol – 5 Dimensions; PTS = postthrombotic syndrome; QoL = quality of life. See Table 1 and 4 legends for expansion of other abbreviations and GRADE Working Group grades of evidence.

aCI includes values suggesting both benefit and harm.
bLow number of events.
cReported deaths from Enden et al (CAVENT).
dEstimate taken from Watson et al. The 1 study included for this outcome was Enden et al (CAVENT).
eBaseline risks for nonfatal recurrent VTE and for major bleeding derived from Douketis et al.
fMost of bleeding events occur during the first 7 d.
gThis estimate is based on the Watson et al. The 1 study included for this outcome was Enden et al (CAVENT). For PTS at 6 mo, published data from Enden et al (CAVENT) provide an estimate RR of 0.93 (0.61-1.42) via Watson et al.
hThis estimate is based on the findings of the VETO study.
iFor severe PTS, assuming the same RR of 0.46 and a baseline risk of 13.8%, the absolute reduction is 75 fewer severe PTS per 1,000 (from 29 fewer to 138 fewer) over 2 y.

jReported patency from Enden et al (CAVENT).
kOpen-label.
lDisease-specific QoL (VEINES-QOL) estimate used at 24 mo according to treatment allocation.
mGeneric QoL (EQ-5D) at 24 mo according to treatment allocation estimate is mean difference 0.04 (-0.01 to 0.17). Bibliography: Watson et al used for all outcomes except patency and QoL; Enden et al used for patency estimates; Enden et al used for QoL estimates.
TABLE 15  Risk Factors for Bleeding With, and Contraindications to Use of, Thrombolytic Therapy (Both Systemic and Locally Administered)

<table>
<thead>
<tr>
<th>Major Contraindications&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Relative contraindications&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural intracranial disease</td>
<td>Systolic BP &gt;180</td>
</tr>
<tr>
<td>Previous intracranial hemorrhage</td>
<td>Diastolic BP &gt;110</td>
</tr>
<tr>
<td>Ischemic stroke within 3 mo</td>
<td>Recent bleeding (nonintracranial)</td>
</tr>
<tr>
<td>Active bleeding</td>
<td>Recent surgery</td>
</tr>
<tr>
<td>Recent brain or spinal surgery</td>
<td>Recent invasive procedure</td>
</tr>
<tr>
<td>Recent head trauma with fracture</td>
<td>Ischemic stroke more than 3 mo</td>
</tr>
<tr>
<td>or brain injury</td>
<td>Anticoagulated (eg, VKA therapy)</td>
</tr>
<tr>
<td>Bleeding diathesis</td>
<td>Traumatic cardiopulmonary resuscitation</td>
</tr>
<tr>
<td>Pericarditis or pericardial fluid</td>
<td>Diabetic retinopathy</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Age &gt;75 y</td>
</tr>
<tr>
<td>Low body weight (eg, &lt;60 kg)</td>
<td>Female</td>
</tr>
<tr>
<td>Black race</td>
<td></td>
</tr>
</tbody>
</table>

See Table 1 and 6 legends for expansion of abbreviations and GRADE Working Group grades of evidence.

<sup>a</sup>The presence of major contraindications usually precludes use of thrombolytic therapy; consequently, these factors have not been well studied as risk factors for bleeding associated with thrombolytic therapy. Patients with 1 or more major contraindication are usually considered to be “high risk for bleeding with thrombolytic therapy.” The factors listed in this table are consistent with other recommendations for the use of thrombolytic therapy in patients with PE<sup>138,233-235</sup>.<sup>b</sup>Risk factors for bleeding during anticoagulant therapy that are noted in Table 11 that are not included in this table are also likely to be relative contraindications to thrombolytic therapy. The increase in bleeding associated with a risk factor will vary with: (1) severity of the risk factor (eg, extent of trauma or recent surgery) and (2) temporal relationships (eg, interval from surgery or a previous bleeding episode; believed to decrease markedly after approximately 2 wk). Risk factors for bleeding at critical sites (eg, intracranial, intraocular) or noncompressible sites are stronger contraindications for thrombolytic therapy. Depending on the nature, severity, temporality, and number of relative contraindications, patients may be considered “high risk of bleeding with thrombolytic therapy” or “non-high risk for thrombolytic therapy.” Patients with no risk factors, 1-2 minor risk factors (eg, female and black race) are usually considered “low risk of bleeding with thrombolytic therapy.” Among 32,000 Medicare patients (≥65 y) with myocardial infarction who were treated with thrombolytic therapy, the following factors were independently associated with intracranial hemorrhage: age ≥75 y (OR, 1.6); black (OR, 1.4); female (OR, 1.4); previous stroke (OR, 1.5); systolic BP ≥150 mm Hg (OR, 1.5); women ≤65 kg or men ≤80 kg (OR, 1.5); INR ≥4 (OR, 2.2).<sup>15</sup> The rate of intracranial hemorrhage increased from 0.7% with 0 or 1 of these risk factors, to 4.1% with ≥5 risk factors. Among 32,000 patients with myocardial infarction who were treated with thrombolytic therapy in 5 clinical trials, the following factors were independently associated with moderate or severe bleeding: older age (OR, 1.04 per year); black (OR, 1.4); female (OR, 1.5); hypertension (OR, 1.2); lower weight (OR, 0.99 per kg).<sup>13</sup> We estimate that systemic thrombolytic therapy is associated with relative risk of major bleeding of 3.5 within 35 d (RR, approximately 2 for intracranial bleeding); about three-quarters of the excess of major bleeds with thrombolytic therapy occur in the first 24 h.<sup>141</sup>

uncertain, we consider that anticoagulant therapy alone is an acceptable alternative to CDT in all patients with acute DVT who do not have impending venous gangrene.

16. In patients with acute proximal DVT of the leg, we suggest anticoagulant therapy alone over CDT (Grade 2C).

Remarks: Patients who are most likely to benefit from CDT (see text), who attach a high value to prevention of PTS, and a lower value to the initial complexity, cost, and risk of bleeding with CDT, are likely to choose CDT over anticoagulation alone.

Role of IVC Filter in Addition to Anticoagulation for Acute DVT or PE

Summary of the Evidence

Our recommendation in AT9 was primarily based on findings of the Prevention du Risque d’Embolie Pulmonaire par Interruption Cave (PREPIC) randomized trial,<sup>95,96</sup> which showed that placement of a permanent IVC filter increased DVT, decreased PE, and did not influence VTE (DVT and PE combined) or mortality. Since then, several registries have suggested that IVC filters can reduce early mortality in patients with acute VTE, although this evidence has been questioned.<sup>97-101</sup> The recently published PREPIC 2 randomized trial found that placement of an IVC filter for 3 months did not reduce recurrent PE, including fatal PE, in anticoagulated patients with PE and DVT who had additional risk factors for recurrent VTE (Table 16, e-Table 16).<sup>102</sup> This new evidence is consistent with our recommendations in AT9. However, because it is uncertain if there is benefit to placement of an IVC filter in anticoagulated patients with severe PE (eg, with hypotension), and this is done by some experts, our recommendation against insertion of an IVC filter in patients with acute PE who are anticoagulated may not apply to this select subgroup of patients.

Although the PREPIC 2 study has improved the quality of evidence for this recommendation, overall quality is still moderate because of imprecision (Table 16, e-Table 16). The AT10 panel decided against combining the results of
the PREPIC and PREPIC 2 studies because of differences in the type of filter used, the duration of filter placement, and differences in the length of follow-up.

17. In patients with acute DVT or PE who are treated with anticoagulants, we recommend against the use of an IVC filter (Grade 1B).

**Compression Stocking to Prevent PTS**

**Summary of the Evidence**

AT9 suggested routine use of graduated compression stockings for 2 years after DVT to reduce the risk of PTS. That recommendation was mainly based on findings of two small, single-center, randomized trials in which patients and study personnel were not blinded to stocking use (no placebo stocking). The quality of the evidence was moderate because of risk of bias resulting from a lack of blinding of an outcome (PTS) that has a large subjective component and because of serious imprecision of the combined findings of the two trials (Table 17, e-Table 17). Since AT9, a much larger multicenter, placebo-controlled trial at low risk of bias found that routine use of graduated compression stockings did not reduce PTS or have other important benefits. Based on this trial, we now suggest that graduated compression stockings not be used routinely to prevent PTS and consider the quality to the evidence to be moderate (Table 17, e-Table 17).

The same study found that routine use of graduated compression stockings did not reduce leg pain during the 3 months after DVT diagnosis (Table 17, e-Tables 2 and 17). This finding, however, does not mean that graduated compression stockings will not reduce acute symptoms of DVT or chronic symptoms in those who have developed PTS.

**Remarks:** This recommendation focuses on prevention of the chronic complication of PTS and not on the treatment of symptoms. For patients with acute or chronic symptoms, a trial of graduated compression stockings is often justified.

**Whether to Treat Subsegmental PE**

**Summary of the Evidence**

Subsegmental PE refers to PE that is confined to the subsegmental pulmonary arteries. Whether these patients should be treated, a question that was not addressed in AT9, has grown in importance because improvements in CT pulmonary angiography have increased how often subsegmental PE is diagnosed (ie, from approximately 5% to more than 10% of...
There is uncertainty whether these patients should be anticoagulated for two reasons. First, because the abnormalities are small, a diagnosis of subsegmental PE is more likely to be a false-positive finding than a diagnosis of PE in the segmental or more proximal pulmonary arteries. Second, because a true subsegmental PE is likely to have arisen from a small DVT, the risk of progressive or recurrent VTE without anticoagulation is expected to be lower than in patients with a larger PE. Our literature search did not identify any randomized trials in patients with subsegmental PE. There is, however, high-quality evidence for the efficacy and safety of anticoagulant therapy in patients with larger PE, and this is expected to apply similarly to patients with subsegmental PE. Whether the risk of progressive or recurrent VTE is high enough to justify anticoagulation in patients with subsegmental PE is uncertain. There were no episodes of recurrent VTE in retrospective reports that included about 60

### TABLE 17

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Follow-up</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PTS Villalta Score</strong></td>
<td>803 (1 study)</td>
<td>6 mo</td>
<td>Moderate because of imprecision</td>
<td>RR 1.01 (0.86-1.18)</td>
<td>Moderate-Risk Population</td>
</tr>
<tr>
<td><strong>Recurrent VTE</strong></td>
<td>803 (1 study)</td>
<td>6 mo</td>
<td>Moderate because of imprecision</td>
<td>RR 0.84 (0.54-1.31)</td>
<td>479 per 1,000</td>
</tr>
<tr>
<td><strong>Acute Leg Pain</strong></td>
<td>742 (1 study)</td>
<td>60 d</td>
<td>Moderate because of imprecision</td>
<td>The mean acute leg pain</td>
<td></td>
</tr>
<tr>
<td><strong>QoL</strong></td>
<td>803 (1 study)</td>
<td></td>
<td>High</td>
<td>The mean QoL in the</td>
<td></td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ECS = elastic compression stockings; SF-36 = Short Form 36. See Table 1 and 14 legends for expansion of other abbreviations and GRADE Working Group grades of evidence.

*For included studies, number of PTS events as assessed by Villalta’s criteria

**Low number of events.

*There were 3 studies originally included for this outcome (Brandjes et al,103 Prandoni et al,104 and Kahn et al106 [SOX]). There was very high heterogeneity among the 3 studies, P = 92% (P < .01). The pooled effect of the 3 studies was RR, 0.63 (0.35-1.13). Yet, because of the high risk of bias associated with Brandjes et al103 and Prandoni et al,104 it was decided to focus on the estimate of the low-risk trial, Kahn et al106 (SOX), which is used here.

*This estimate is based on the findings of the VETO study.232

*CI includes values suggesting no effect and values suggesting either benefit or harm.

*There were 3 studies originally included for this outcome (Brandjes et al,103 Prandoni et al,104 and Kahn et al106 [SOX]). The pooled effect of the 3 studies was RR, 0.91 (0.65-1.27). Yet, because of the high risk of bias associated with Brandjes et al103 and Prandoni et al,104 it was decided to focus on the estimate of the low-risk trial, Kahn et al106 (SOX), which is used here.

*This estimate is the mean of 2 estimates derived from 2 studies: 12.4% probable/definite VTE170 and 29.1% confirmed VTE.53

*Wide CI that includes no effect.

*Estimate derived from Kahn et al.107

*Estimate based on VEINES-QOL score improvement of 5.8 points (SD, 7.5) for active ECS vs 5.9 (SD, 7.1) for placebo ECS.

*SF-36 physical component score improved by 8.4 points (SD, 13.6) for active ECS vs 9.9 (SD, 13.2) for placebo ECS (difference between groups of -1.53 points, 95% CI, -3.44 to 0.39; P = .12). Bibliography: Kahn et al106 (SOX) for PTS and recurrent VTE; Kahn et al107 for acute leg pain.
patients with subsegmental PE and no proximal DVT and who were not anticoagulated. However, in another retrospective analysis, patients with subsegmental PE appeared to have a similar risk of recurrent VTE during 3 months of anticoagulant therapy as patients with larger PE, and a higher risk than in patients who were suspected of having PE but had PE excluded.

The AT10 panel endorsed that, if no anticoagulant therapy is an option, patients with subsegmental PE should have bilateral US examinations to exclude proximal DVT of the legs. DVT should also be excluded in other high-risk locations, such as in upper extremities with central venous catheters. If DVT is detected, patients require anticoagulation. If DVT is not detected, there is uncertainty whether patients should be anticoagulated. If a decision is made not to anticoagulate, there is the option of doing one or more follow-up US examinations of the legs to detect (and then treat) evolving proximal DVT. Serial testing for proximal DVT has been shown to be a safe management strategy in patients with suspected PE who have nondiagnostic ventilation-perfusion scans, many of whom are expected to have subsegmental PE.

We suggest that a diagnosis of subsegmental PE is more likely to be correct (ie, a true positive) if: (1) the CT pulmonary angiogram is of high quality with good opacification of the distal pulmonary arteries; (2) there are multiple intraluminal defects; (3) defects involve more proximal subsegmental arteries (ie, are larger); (4) defects are seen on more than one image; (5) defects are surrounded by contrast rather than appearing to be adherent to the pulmonary artery walls; (6) defects are seen on more than one projection; (7) patients are symptomatic, as opposed to PE being an incidental finding; (8) there is a high clinical pretest probability for PE; and (9) D-dimer level is elevated, particularly if the increase is marked and otherwise unexplained.

In addition to whether or not patients truly have subsegmental PE, we consider the following to be risk factors for recurrent or progressive VTE if patients are not anticoagulated—patients who: are hospitalized or have reduced mobility for another reason; have active cancer (particularly if metastatic or being treated with chemotherapy); or have no reversible risk factor for VTE such as recent surgery. Furthermore, a low cardiopulmonary reserve or marked symptoms that cannot be attributed to another condition favors no anticoagulant therapy. The decision to anticoagulate or not is also expected to be sensitive to patient preferences. Patients who are not anticoagulated should be told to return for reevaluation if symptoms persist or worsen.

The evidence supporting our recommendations is low quality because of indirectness and because there is limited ability to predict which patients will have VTE complications without anticoagulation.

In patients with subsegmental PE (no involvement of more proximal pulmonary arteries) and no proximal DVT in the legs who have a (i) low risk for recurrent VTE (see text), we suggest clinical surveillance over anticoagulation (Grade 2C), and (ii) high risk for recurrent VTE (see text), we suggest anticoagulation over clinical surveillance (Grade 2C).

Remarks: US imaging of the deep veins of both legs should be done to exclude proximal DVT. Clinical surveillance can be supplemented by serial US imaging of the proximal deep veins of both legs to detect evolving DVT (see text). Patients and physicians are more likely to opt for clinical surveillance over anticoagulation if there is good cardiopulmonary reserve or a high risk of bleeding.

Treatment of Acute PE Out of the Hospital

Summary of the Evidence

Our recommendation in AT9 was based on: (1) two trials that randomized patients with acute PE to receive LMWH for only 3 days in the hospital or entirely at home compared with being treated with LMWH in the hospital for a longer period; (2) 15 observational studies, 9 of which were prospective, that evaluated treatment of acute PE out of the hospital; and (3) longstanding experience treating DVT without admission to a hospital. Since AT9, no further randomized trials have evaluated out-of-hospital treatment of acute PE. Several additional prospective and retrospective observational studies have reported findings consistent with earlier reports, and the findings of all of these studies have been included in recent meta-analyses that have addressed treatment of acute PE out of the hospital.

Studies that evaluated NOACs for the acute treatment of PE did not report the proportion of patients who were treated entirely out of hospital, but it is probable that
this was uncommon. Treatment of acute PE with a NOAC that does not require initial heparin therapy (eg, rivaroxaban, apixaban) facilitates treatment without hospital admission. Consistent with AT9, we suggest that patients who satisfy all of the following criteria are suitable for treatment of acute PE out of the hospital: (1) clinically stable with good cardiopulmonary reserve; (2) no contraindications such as recent bleeding, severe renal or liver disease, or severe thrombocytopenia (ie, <70,000/mm³); (3) expected to be compliant with treatment; and (4) the patient feels well enough to be treated at home. Clinical decision rules such as the Pulmonary Embolism Severity Index (PESI), either the original form with score <85 or the simplified form with score of 0, can help to identify low-risk patients who are suitable for treatment at home.126-131 However, we consider clinical prediction rules as aids to decision-making and do not require patients to have a predefined score (eg, low-risk PESI score) to be considered for treatment at home. Similarly, although we do not suggest the need for routine assessment in patients with acute PE, we agree that the presence of right ventricular dysfunction or increased cardiac biomarker levels should discourage treatment out of the hospital.130,132-138 The quality of the evidence for treatment of acute PE at home remains moderate because of marked imprecision. The updated recommendation has been modified to state that appropriately selected patients may be treated entirely at home, rather than just be discharged early.

*20. In patients with low-risk PE and whose home circumstances are adequate, we suggest treatment at home or early discharge over standard discharge (eg, after the first 5 days of treatment) (Grade 2B).

Systemic Thrombolytic Therapy for PE

Summary of the Evidence

It has long been established that systemic thrombolytic therapy accelerates resolution of PE as evidenced by more rapid lowering of pulmonary artery pressure, increases in arterial oxygenation, and resolution of perfusion scan defects, and that this therapy increases mortality benefit of thrombolytic therapy in patients with acute PE, however, has been uncertain and depends on an individual patient’s baseline (ie, without thrombolytic therapy) risk of dying from acute PE and risk of bleeding. Patients with the highest risk of dying from PE and the lowest risk of bleeding obtain the greatest net benefit from thrombolytic therapy. Patients with the lowest risk of dying from PE and the highest risk of bleeding obtain the least net benefit from thrombolytic therapy and are likely to be harmed.

Evidence for the Use of Thrombolytic Therapy in Patients With Acute PE: AT9 recommendations for the use of thrombolytic therapy in acute PE were based on low-quality evidence.1,139 At that time, only about 800 patients with acute PE had been randomized to receive thrombolytic therapy or anticoagulant therapy alone and, consequently, estimates of efficacy, safety, and overall mortality were very imprecise. In addition, the trials that enrolled these 800 patients had a high risk of bias and there was a strong suspicion that there was selective reporting of studies that favored thrombolytic therapy (ie, publication bias). Randomized trials have clearly established that thrombolytic therapy increases bleeding in patients with acute myocardial infarction,140 but that evidence was indirect when applied to patients with PE.

Since AT9, two additional small, randomized trials141,142 and a much larger trial143 have evaluated systemic thrombolytic therapy in about 1,200 patients with acute PE. The findings of these new studies have been combined with those of earlier studies in a number of meta-analyses.144-148 These new data, by reducing imprecision for estimates of efficacy and safety and the overall risk of bias, have increased the quality of the evidence from low to moderate for recommendations about the use of systemic thrombolytic therapy in acute PE (Table 18, e-Table 18).

Most of the new evidence comes from the Pulmonary Embolism Thrombolysis trial, which randomized 1,006 patients with PE and right ventricular dysfunction to tenecteplase and heparin or to heparin therapy alone (with placebo).143 The most notable findings of this study were that thrombolytic therapy prevented cardiovascular collapse but increased major (including intracranial) bleeding; these benefits and harms were finely balanced, with no convincing net benefit from thrombolytic therapy. An additional finding was that “rescue thrombolytic therapy” appeared to be of benefit in patients who developed cardiovascular collapse after initially being treated with anticoagulant therapy alone.

Management Implication of the Updated Evidence: The improved quality of evidence has not resulted in substantial changes to our recommendations because: (1) the new data support that the benefits of systemic thrombolytic therapy in patients without hypotension, including those with right ventricular dysfunction or an increase in cardiac biomarkers ("intermediate-risk PE"),
are largely offset by the increase in bleeding; and (2) among patients without hypotension, it is still not possible to confidently identify those who will derive net benefit from this therapy.

**PE Without Hypotension:** Consistent with AT9, we recommend that most patients with acute PE who do not have hypotension are not treated with thrombolytic therapy. However, patients with PE without hypotension include a broad spectrum of presentations. At the mild end of the spectrum are those who have minimal symptoms and minimal cardiopulmonary impairment. As noted in the section “Setting for initial anticoagulation for PE,” many of these patients can be treated entirely at home or can be discharged after a brief admission. At the severe end of the spectrum are those with severe symptoms and more marked cardiopulmonary impairment (even though systolic BP is >90 mm Hg). In addition to clinical features of cardiopulmonary impairment (eg, heart rate, BP, respiratory rate, jugular venous pressure, tissue hypoperfusion, pulse oximetry), they may have evidence of right ventricular dysfunction on their CT pulmonary angiogram or on echocardiography, or evidence of myocardial damage as reflected by increases in cardiac biomarkers (eg, troponins, brain natriuretic peptide).

**PE With Hypotension:** Consistent with AT9, we suggest that patients with acute PE with hypotension (ie, systolic BP <90 mm Hg for 15 min) and without high bleeding risk (Table 15) are treated with thrombolytic therapy. The more severe and persistent the hypotension, and the more marked the associated features of shock and myocardial dysfunction or damage, the more compelling the indication for systemic thrombolytic therapy. Conversely, if hypotension is transient or less marked, not associated with features of shock or myocardial dysfunction, and if there are risk factors for bleeding, physicians and patients are likely to initially choose anticoagulant therapy without thrombolytic therapy. If thrombolytic therapy is not used and hypotension persists or becomes more marked, or clinical features of shock or myocardial damage develop or worsen, thrombolytic therapy may then be used.

### Table 18: Summary of Findings: Systemic Thrombolytic Therapy vs Anticoagulation Alone for Acute PE

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of Participants (Studies)</th>
<th>Quality of the Evidence (GRADE)</th>
<th>Relative Effect (95% CI)</th>
<th>Risk with Anticoagulation Alone</th>
<th>Risk Difference with Systemic Thrombolytic Therapy (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>2,115 (17 studies)</td>
<td>Moderate</td>
<td>OR 0.53 (0.32-0.88)</td>
<td>39 per 1,000</td>
<td>18 fewer per 1,000</td>
<td>18 fewer per 1,000 (from 5 fewer to 26 fewer)</td>
</tr>
<tr>
<td>Recurrent PE</td>
<td>2,043 (15 studies)</td>
<td>Moderate</td>
<td>OR 0.40 (0.22-0.74)</td>
<td>30 per 1,000</td>
<td>18 fewer per 1,000</td>
<td>18 fewer per 1,000 (from 8 fewer to 24 fewer)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>2,115 (16 studies)</td>
<td>High</td>
<td>OR 2.73 (1.91-3.91)</td>
<td>34 per 1,000</td>
<td>54 more per 1,000</td>
<td>54 more per 1,000 (from 29 more to 87 more)</td>
</tr>
<tr>
<td>Intracranial</td>
<td>2,043 (15 studies)</td>
<td>Moderate</td>
<td>OR 4.63 (1.78-12.04)</td>
<td>2 per 1,000</td>
<td>7 more per 1,000</td>
<td>7 more per 1,000 (from 2 more to 21 more)</td>
</tr>
</tbody>
</table>

The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence.

- Low number of events.
- Estimate from Chatterjee et al. Other estimates from meta-analyses on this topic include Dong et al: OR, 0.89 (0.45-1.78); Cao et al: RR, 0.64 (0.29-1.40); Marti et al: OR, 0.59 (0.36-0.96); Nakamura et al: RR, 0.72 (0.39-1.31); Chatterjee et al (intermediate-risk PE only): OR, 0.46 (0.25-0.92); Marti et al (intermediate-risk PE only): OR, 0.42 (0.17-1.03).
- Majority (83%) of participants in Chatterjee et al were “moderate” risk.
- Estimate from Chatterjee et al. Other estimates from meta-analyses on this topic include Dong et al: OR, 0.63 (0.33-1.20); Cao et al: RR 0.44 (0.19-1.05); Marti et al: OR, 0.50 (0.27-0.94); Nakamura et al: RR, 0.60 (0.21-1.69).
- Estimate from Chatterjee et al. Other estimates from meta-analyses on this topic include Dong et al: OR, 1.61 (0.91-2.86); Cao et al: RR, 1.16 (0.51-2.60); Marti et al: OR, 2.91 (1.95-4.36); Nakamura et al: RR, 2.07 (0.58-7.35).
- Estimate from Chatterjee et al. Bibliography: Chatterjee et al.
We suggest that patients without hypotension who are at the severe end of the spectrum be treated with aggressive anticoagulation and other supportive measures, and not with thrombolytic therapy. These patients need to be closely monitored to ensure that deteriorations are detected. Development of hypotension suggests that thrombolytic therapy has become indicated. Deterioration that has not resulted in hypotension may also prompt the use of thrombolytic therapy. For example, there may be a progressive increase in heart rate, a decrease in systolic BP (which remains >90 mm Hg), an increase in jugular venous pressure, worsening gas exchange, signs of shock (eg, cold sweaty skin, reduced urine output, confusion), progressive right heart dysfunction on echocardiography, or an increase in cardiac biomarkers.

We do not propose that echocardiography or cardiac biomarkers are measured routinely in all patients with PE, or in all patients with a non–low-risk PESI assessment. This is because, when measured routinely, the results of these assessments do not have clear therapeutic implications. For example, we do not recommend thrombolytic therapy routinely for patients without hypotension who have right ventricular dysfunction and an increase in cardiac biomarkers. However, we encourage assessment of right ventricular function by echocardiography and/or measurement of cardiac biomarkers if, following clinical assessment, there is uncertainty about whether patients require more intensive monitoring or should receive thrombolytic therapy.

21. In patients with acute PE associated with hypotension (eg, systolic BP < 90 mm Hg) who do not have a high bleeding risk, we suggest systemically administered thrombolytic therapy over no such therapy (Grade 2B).

*22. In most patients with acute PE not associated with hypotension, we recommend against systemically administered thrombolytic therapy (Grade 1B).

*23. In selected patients with acute PE who deteriorate after starting anticoagulant therapy but have yet to develop hypotension and who have a low bleeding risk, we suggest systemically administered thrombolytic therapy over no such therapy (Grade 2C).

Remarks: Patients with PE and without hypotension who have severe symptoms or marked cardiopulmonary impairment should be monitored closely for deterioration. Development of hypotension suggests that thrombolytic therapy has become indicated. Cardiopulmonary deterioration (eg, symptoms, vital signs, tissue perfusion, gas exchange, cardiac biomarkers) that has not progressed to hypotension may also alter the risk-benefit assessment in favor of thrombolytic therapy in patients initially treated with anticoagulation alone.

Catheter-Based Thrombus Removal for the Initial Treatment of PE

Summary of the Evidence

Interventional catheter-based treatments for acute PE include delivery of CDT if there is not a high risk of bleeding, or catheter-based treatment without thrombolytic therapy if there is a high risk of bleeding.

CDT: The most important limitation of systemic thrombolytic therapy is that it increases bleeding, including intracranial bleeding. CDT, because it uses a lower dose of thrombolytic drug (eg, about one-third), is expected to cause less bleeding at remote sites (eg, intracranial, GI). CDT, however, may be as or more effective than systemic thrombolytic therapy for two reasons: (1) it achieves a high local concentration of thrombolytic drug by infusing drug directly into the PE and (2) thrombus fragmentation resulting from placement of the infusion catheter in the thrombus or additional maneuvers, or an increase in thrombus permeability from US delivered via the catheter, may enhance endogenous or pharmacologic thrombolysis. Thrombolytic therapy is usually infused over many hours or overnight. In emergent situations, systemic thrombolytic therapy can be given while CDT is being arranged, and active thrombus fragmentation and aspiration (see below) can be combined with CDT.

A single randomized trial of 59 patients found that, compared with anticoagulation alone, US-assisted CDT improved right ventricular function at 24 h. Observational studies also suggest that CDT is effective at removing thrombus, lowering pulmonary arterial pressure, and improving right ventricular function without being associated with a high risk of bleeding. Most of these studies are small (fewer than 30 patients) and retrospective, although a recent prospective registry of 101 patients and a prospective cohort study of 150 patients also support the efficacy of CDT. Whereas there was no major bleeding in the registry, there were 15 episodes in the cohort study.
An older randomized trial of 34 patients with massive PE found that infusion of recombinant tissue plasminogen activator into a pulmonary artery as opposed to a peripheral vein did not accelerate thrombolysis, but caused more frequent bleeding at the catheter insertion site.\textsuperscript{157} No randomized trials or observational studies have compared contemporary CDT with systemic thrombolytic therapy. For patients who require thrombolytic therapy and do not have a high risk of bleeding, the AT10 panel favored systemic thrombolytic therapy over CDT because, compared with anticoagulation alone, there is a higher quality of evidence in support of systemic thrombolytic therapy than for CDT.

**Catheter-Based Thrombus Removal Without Thrombolytic Therapy:** Catheter-based mechanical techniques for thrombus removal involve thrombus fragmentation using various types of catheters, some of which are designed specifically for this purpose.\textsuperscript{150-153} Fragmentation results in distal displacement of thrombus, with or without suctioning and removal of some thrombus through the catheter. Mechanical methods alone are used when thrombus removal is indicated but there is a high risk of bleeding that precludes thrombolytic therapy. No randomized trial or prospective cohort studies have evaluated catheter-based thrombus removal of PE without thrombolytic therapy.

Evidence for the use of CDT compared with anticoagulation alone, CDT compared with systemic thrombolytic therapy, and catheter-based treatment without thrombolytic therapy is of low quality and our recommendations are weak.

*24. In patients with acute PE who are treated with a thrombolytic agent, we suggest systemic thrombolytic therapy using a peripheral vein over CDT (Grade 2C).

**Remarks:** Patients who have a higher risk of bleeding with systemic thrombolytic therapy, and who have access to the expertise and resources required to do CDT, are likely to choose CDT over systemic thrombolytic therapy.

*25. In patients with acute PE associated with hypotension and who have (i) a high bleeding risk, (ii) failed systemic thrombolysis, or (iii) shock that is likely to cause death before systemic thrombolysis can take effect (eg, within hours), if appropriate expertise and resources are available, we suggest catheter-assisted thrombus removal over no such intervention (Grade 2C).

**Remarks:** Catheter-assisted thrombus removal refers to mechanical interventions, with or without catheter directed thrombolysis.

**Pulmonary Thromboendarterectomy in for the Treatment of Chronic Thromboembolic Pulmonary Hypertension**

**Summary of the Evidence**

The AT9 recommendation was based on case series that have shown marked improvements in cardiopulmonary status after thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension (CTEPH).\textsuperscript{158,159} Although additional case series have been reported, the quality of the evidence for thromboendarterectomy in patients with CTEPH has not improved.\textsuperscript{153,160-162} The AT10 panel decided, however, that our previous recommendation for thromboendarterectomy in selected patients with CTEPH was too restrictive and could contribute to suboptimal evaluation and treatment of patients with CTEPH. For example, because of improvements in surgical technique, it is now often possible to remove organized thrombi from peripheral pulmonary arteries. In patients with inoperable CTEPH or persistent pulmonary hypertension after pulmonary thromboendarterectomy, there is new evidence from a randomized trial that pulmonary vasodilator therapy may be of benefit.\textsuperscript{163} For these reasons, we no longer identify central disease as a selection factor for thromboendarterectomy in patients with CTEPH, and we emphasize that patients with CTEPH should be assessed by a team with expertise in the evaluation and management of pulmonary hypertension.\textsuperscript{153,159,164-166}

*26. In selected patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are identified by an experienced thromboendarterectomy team, we suggest pulmonary thromboendarterectomy over no pulmonary thromboendarterectomy (Grade 2C).

**Remarks:** Patients with CTEPH should be evaluated by a team with expertise in treatment of pulmonary hypertension. Pulmonary thromboendarterectomy is often lifesaving and life-transforming. Patients with
CTEPH who are not candidates for pulmonary thromboendarterectomy may benefit from other mechanical and pharmacological interventions designed to lower pulmonary arterial pressure.

Thrombolytic Therapy in Patients With Upper Extremity DVT

Summary of the Evidence

The AT9 recommendation was based on: (1) mostly retrospective observational studies suggesting that thrombolysis could improve short- and long-term venous patency, but a lack of data about whether thrombolysis reduced PTS of the arm; (2) occasional reports of bleeding in patients with UEDVT who were treated with thrombolysis, and clear evidence that thrombolysis increases bleeding in other settings; and (3) recognition that, compared to anticoagulation alone, thrombolytic therapy is complex and costly.\(^1,167,168^\) We suggest that thrombolysis is most likely to be of benefit in patients who meet the following criteria: severe symptoms; thrombus involving most of the subclavian vein and the axillary vein; symptoms for <14 days; good functional status; life expectancy of ≥1 year; and low risk for bleeding. We also suggested CDT over systemic thrombolysis to reduce the dose of thrombolytic drug and the risk of bleeding. There is new moderate quality evidence that CDT can reduce PTS of the leg\(^90^\) (Table 14, e-Table 15) and that systemic thrombolysis increases bleeding in patients with acute PE;\(^143,147^\) and low-quality evidence that CDT can accelerate breakdown of acute PE.\(^154^\) This evidence has indirect bearing on thrombolysis in patients with UEDVT, but it has not changed the overall quality of the evidence or our recommendations for use of thrombolysis in these patients.

27. In patients with acute upper extremity DVT (UEDVT) that involves the axillary or more proximal veins, we suggest anticoagulant therapy alone over thrombolysis (Grade 2C).

Remarks: Patients who (i) are most likely to benefit from thrombolysis (see text); (ii) have access to CDT; (iii) attach a high value to prevention of PTS; and (iv) attach a lower value to the initial complexity, cost, and risk of bleeding with thrombolytic therapy are likely to choose thrombolytic therapy over anticoagulation alone.

28. In patients with UEDVT who do not undergo thrombolysis with UEDVT who do not undergo thrombolysis (Grade 1B).

Management of Recurrent VTE on Anticoagulant Therapy

Summary of Evidence

There are no randomized trials or prospective cohort studies that have evaluated management of patients with recurrent VTE on anticoagulant therapy. Consequently, management is based on low-quality evidence and an assessment of the probable reason for the recurrence. Risk factors for recurrent VTE while on anticoagulant therapy can be divided into two broad categories: (1) treatment factors and (2) the patient’s intrinsic risk of recurrence. How a new event should be treated will depend on the reason(s) for recurrence.

Treatment Factors: The risk of recurrent VTE decreases rapidly after starting anticoagulant therapy, with a much higher risk during the first week (or month) compared with the second week (or month).\(^169,170^\) A recurrence soon after starting therapy can generally be managed by a time-limited (eg, 1 month) period of more aggressive anticoagulant intensity (eg, switching from an oral agent back to LMWH, an increase in LMWH dose). Other treatment factors that are associated with recurrent VTE and will suggest specific approaches to management include: (1) was LMWH being used; (2) was the patient adherent; (3) was VKA subtherapeutic; (4) was anticoagulant therapy prescribed correctly; (5) was the patient taking an NOAC and a drug that reduced anticoagulant effect; and (6) had anticoagulant dose been reduced (drugs other than VKA)?

There is moderate-quality evidence that LMWH is more effective than VKA therapy in patients with VTE and cancer. A switch to full-dose LMWH, therefore, is often made if there has been an unexplained recurrent VTE on VKA therapy or an NOAC. If the recurrence happened on LMWH, the dose of LMWH can be increased. If the dose of LMWH was previously reduced (eg, by 25% after 1 month of treatment), it is usually increased to the previous level. If the patient was receiving full-dose LMWH, the dose may be increased by about 25%. In practice, the increase in dose is often influenced by the LMWH prefilled syringe dose options that are available. Once-daily LMWH may also be switched to a twice-daily regimen, particularly if two injections are required to deliver the increase in LMWH dose. Treatment adherence, including compliance, can be difficult to assess; for example, symptoms of a recurrent DVT may
encourage medication adherence and a return of coagulation results to the “therapeutic range.”

**Patient Factors:** The most important intrinsic risk factor for recurrent VTE while on anticoagulant therapy is active cancer, with an unexplained recurrence often pointing to yet-to-be-diagnosed disease. Antiphospholipid syndrome is also associated with recurrent VTE, either because of associated hypercoagulability or because a lupus anticoagulant has led to underdosing of VKA because of spurious increases in INR results. Anticoagulated patients may be taking medications that increase the risk of thrombosis such as estrogens or cancer chemotherapy, in which case these treatments may be withdrawn.

A retrospective observational study found an acceptable risk of recurrence (8.6%) and major bleeding (1.4%) during 3 months of follow-up in 70 cancer patients with recurrent VTE while on anticoagulant therapy who either switched from VKA therapy to LMWH (23 patients) or had their LMWH dose increased by about 25% (47 patients). If there is no reversible reason for recurrent VTE while on anticoagulant therapy, and anticoagulant intensity cannot be increased because of risk of bleeding, a vena caval filter can be inserted to prevent PE. However, it is not known if insertion of a filter in these circumstances is worthwhile, and the AT10 panel consider this an option of last resort.

**29. In patients who have recurrent VTE on VKA therapy (in the therapeutic range) or on dabigatran, rivaroxaban, apixaban, or edoxaban (and are believed to be compliant), we suggest switching to treatment with LMWH at least temporarily** (Grade 2C).

**Remarks:** Recurrent VTE while on therapeutic-dose anticoagulant therapy is unusual and should prompt the following assessments: (1) reevaluation of whether there truly was a recurrent VTE; (2) evaluation of compliance with anticoagulant therapy; and (3) consideration of an underlying malignancy. A temporary switch to LMWH will usually be for at least 1 month.

**30. In patients who have recurrent VTE on long-term LMWH (and are believed to be compliant), we suggest increasing the dose of LMWH by about one-quarter to one-third** (Grade 2C).

**Remarks:** Recurrent VTE while on therapeutic-dose anticoagulant therapy is unusual and should prompt the following assessments: (1) reevaluation of whether there truly was a recurrent VTE; (2) evaluation of compliance with anticoagulant therapy; and (3) consideration of an underlying malignancy.

**Conclusion**

There is substantial new evidence since AT9 about how to treat VTE. This evidence led the panel to change many of the AT9 recommendations that are included in this update, and has strengthened the evidence quality that underlies others that are unchanged. We now suggest the use of NOACs over VKA for the treatment of VTE in patients without cancer. Although we still suggest LMWH as the preferred long-term treatment for VTE and cancer, we no longer suggest VKA over NOACs in these patients. Although we note factors in individual patients that may favor selection of one NOAC over another in patients without or with cancer, or may favor selection of either a NOAC or VKA in patients with cancer, we have not expressed an overall preference for one NOAC over another, or for either a NOAC or VKA in patients with cancer, because: (1) there are no direct comparisons of different NOACs; (2) NOACs have not been compared with VKA in a broad spectrum of patients with VTE and cancer; and (3) indirect comparisons have not shown convincingly different outcomes with different NOACs. Another notable change in AT10 is that, based on a new low risk of bias study, we now suggest that graduated compression stocking are not routinely used to prevent PTS. Recommendations that are unchanged but are now supported by better evidence include: (1) discouragement of IVC filter use in anticoagulated patients; (2) encouragement of indefinite anticoagulant therapy after a first unprovoked PE; and (3) discouragement of thrombolytic therapy in PE patients who are not hypotensive and are not deteriorating on anticoagulation.

Of the 54 recommendations that are included in the 30 statements in this update, 20 (38%) are strong recommendations (Grade 1) and none is based on high-quality (Grade A) evidence. The absence of high-quality evidence highlights the need for further research to guide VTE treatment decisions. As new evidence becomes available, these guidelines will need to be updated. Goals of our group and CHEST include transition to continually updated “living guidelines.” The modular format of this update is designed to facilitate this development, with individual topics and questions being addressed as new evidence becomes available. We will also facilitate implementation of our
recommendations into practice by developing new and convenient ways to disseminate our recommendations. This will enable achievement of another of our goals—reduction in the burden of VTE in individual patients and in the general population.

Acknowledgments

Author contributions: C. K. was the chair of the panel. C. K., E. A., A. B., J. O., D. J., and I. M. were executive committee members of the panel. C. K. and N. S. were the topic editors for “Treatment of Acute Pulmonary Embolism Out of Hospital”. C. K. and D. J. were the topic editors for “Pulmonary Thromboendarterectomy in the Treatment of Chronic Thromboembolic Pulmonary Hypertension”. E. A. and A. B. were the topic editors for “Compression Stocking to Prevent Post-Thrombotic Syndrome”. E. K. and A. B. were the topic editors for “Thrombolytic Therapy in Patients with Upper Extremity Deep Vein Thrombosis”. D. J. and C. S. K. were the topic editors for “Management of Recurrent Venous Thromboembolism on Anticoagulant Therapy”. H. B. and N. S. were the topic editors for “Whether and How to Anticoagulate Patients with Isolated Distal Deep Vein Thrombosis”. M. H. and H. B. were the topic editors for “Catheter-Directed Thrombolysis for Acute Deep Vein Thrombosis of the Leg”. M. H. and J. V. were the topic editors for “Duration of Anticoagulant Therapy”. L. M. and C. S. K. were the topic editors for “Whether to Anticoagulate Subsegmental Pulmonary Embolism”. S. S., T. M. and P. W. were the topic editors for “Catheter-Based Thrombus Removal for the Initial Treatment of Pulmonary Embolism”. S. W. and T. M. were the topic editors for “Choice of Long-Term (First 3 Months) and Extended (No Scheduled Stop Date) Anticoagulant”. S. S., S. W. and J. V. were the topic editors for “Systemic Thrombolytic Therapy for Pulmonary Embolism”. L. M. and P. W. were the topic editors for “Aspirin for Extended Treatment of Venous Thromboembolism”. L. M. and C. S. K. were the topic editors for “Role of Inferior Vena Cava Filter in Addition to Anticoagulation in Patients with Acute Deep Vein Thrombosis or Pulmonary Embolism”. E. A. and J. O. were methodologists for the panel. A. B. was the GOC liaison to the panel. L. M. was an overall guideline editor.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following: In the past 3 years, E. A. A. was an author on a number of systematic reviews on anticoagulation in patients with cancer. H. B. has received compensation for participation on advisory committees with speaking engagements sponsored by Sanofi-Aventis, Bayer Healthcare, and Daiichi-Sankyo. His institution has received grant funding (no salary support) from Daiichi-Sankyo for studying VTE treatment. He has also served as a coauthor of original studies using rivaroxaban (EINSTEIN, EINSTEIN Pulmonary Embolism [PE]) and edoxaban (Hokusai-VTE study). M. H. has received grant funding and has delivered talks related to long-term and extended anticoagulation and treatment of subsegmental PE. He has also authored several papers related to long-term and extended anticoagulation, treatment of subsegmental PE, and compression stocking in preventing postthrombotic syndrome. D. J.’s institution has received grant funding (no salary support) from Instituto de salud Carlos III, Sociedad Española de Neumología y Cirugía Torácica, and NeumoMadrid for studying PE. He was a member of Steering Committee of the Pulmonary Embolism Thrombosis Study (PETITHO), a principal investigator of an original study related to the role of the inferior vena cava filter in addition to anticoagulation in patients with acute DVT or PE and has participated in the derivation of scores for identification of low-risk PE. He has delivered talks related to treatment of acute PE. C. K. has been compensated for speaking engagements sponsored by Boehringer Ingelheim and Bayer Healthcare related to VTE therapy. His institution has received grant funding (no salary support) from the National Institutes of Health related to the topic of catheter-assisted thrombus removal in patients with leg DVT. He has also published many studies related to long-term anticoagulation and compression stockings in prevention of postthrombotic syndrome. L. M. has frequently lectured on the duration of long-term anticoagulation and is a coauthor on several risk-stratification papers. She has received honoraria from CHEST Enterprises for VTE talks. T. M. and C. S. K. have received honoraria from Chest Enterprises for VTE Prep Courses. T. M.’s institution has received grant funding (no salary support) from Portola Pharmaceuticals for the Acute Medically III VTE Prevention With Extended Duration Betrixaban Study (APEX) related to extended prophylaxis against VTE with betrixaban. T. M.’s institution received grant support from Bayer Pharmaceuticals for a research project concerning the etiology of chronic thromboembolic pulmonary hypertension. He has also authored textbook chapters related to thrombolytic interventions in patients with acute PE and pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. S. M. S.’s and S. C. W.’s institution has received grant funding (no salary support) from the Canadian Institutes of Health for the D-dimer Optimal Duration Study Phase II (DODS-Extension), from Washington University via the National Institutes of Health (Genetic Informatics Trial), Bayer related to VTE (EINSTEIN studies), and from Bristol-Myers Squibb related to apixaban for the Secondary Prevention of Thromboembolism (Apixaban for the Secondary prevention of Thromboembolism: A prospective Randomized Outcome pilot study among patients with the Antiphospholipid Syndrome). J. R. E. V.’s institution has received grant funding (no salary support) from Bristol-Myers Squibb for evaluating the role of apixaban for long-term treatment of VTE. P. W. is a coinvestigator on a grant regarding the treatment of subsegmental PE. He has authored several studies and grants related to the long-term and extended anticoagulation (using vitamin K antagonists and the direct oral anticoagulants). P. W. has received grant funding from Bristol-Myers Squibb and has received honoraria for talks from Bayer. E. A. A., H. B., C. K., P. W., and S. C. W. participated in the last edition of the CHEST Antithrombotic Therapy for VTE Disease Guidelines (AT9). None declared (A. B., J. O., N. S.).

Role of sponsors: This study was funded in total by internal funds from the American College of Chest Physicians.

Dedication: All of the authors would like to acknowledge the contributions of previous authors of the CHEST Antithrombotic Guidelines.

Additional information: The e-Tables and e-Figures can be found in the Supplemental Materials section of the online article.

References


